{
  "$schema_version": "5.3",
  "review_mode": "fresh",
  "claim_restatement": {
    "index_wording": "Adding Galleri multi-cancer blood screening to usual care reduces cancer mortality in asymptomatic adults aged 50 and older.",
    "entry_form": "claim",
    "gradeable_restatement": "Adding Galleri multi-cancer blood screening to usual care reduces cancer mortality in asymptomatic adults aged 50 and older.",
    "restatement_required": true,
    "split_into": [],
    "parent_claim": null,
    "scope_qualifiers": [
      {
        "qualifier": "Age, symptom status, assay version, screening rounds, comparator, cancer sites and endpoint hierarchy fixed before outcomes",
        "determinable_before_outcome": true,
        "determined_from": "Enrollment and experimental design, before results; no responder-defined scope.",
        "action": "retained"
      }
    ]
  },
  "hypothesis": {
    "name": "Multi-Cancer Blood Screening and Mortality",
    "central_claim": "Adding Galleri multi-cancer blood screening to usual care reduces cancer mortality in asymptomatic adults aged 50 and older.",
    "proposed_mechanism": "Adding Galleri multi-cancer blood screening to usual care reduces cancer mortality in asymptomatic adults aged 50 and older.",
    "claimed_scope": "Adding the specified Galleri assay to usual care in asymptomatic adults aged50 and older, with randomized allocation and adequate cancer-mortality follow-up",
    "claimed_level": [
      "progression",
      "response"
    ],
    "is_conjunctive": false,
    "conjunctive_note": "The precise lead clinical proposition is SC2. Mechanism, competing-cause, generalization and safety companions remain separately reported; they do not replace the primary clinical endpoint."
  },
  "rubric_routing": {
    "primary_rubric": "02-cancer-biology.md",
    "secondary_rubrics": [],
    "index_notes_applied": [
      "The precise lead clinical proposition is SC2. Mechanism, competing-cause, generalization and safety companions remain separately reported; they do not replace the primary clinical endpoint."
    ],
    "rubric_fit_note": "The frozen framework has no screening-mortality rubric. Cancer-rubric biological perturbation wording is quoted unchanged, with an explicit clinical equivalent: randomized addition of the specified screening pathway to usual care with a positive cancer-death effect over adequate follow-up. Diagnostic validation and stage shift are distinct from mortality; tissue-origin accuracy, sensitivity, specificity and predictive values are descriptive properties, not HSEF causal probabilities. No animal lineage experiment is required to evaluate a human screening programme. A descriptive diagnostic appendix accompanies SC1 so the real phenomenon is not graded as refuted."
  },
  "subclaim_matrix": {
    "subclaims": [
      {
        "id": "SC1",
        "statement": "Galleri-detected signals translate into clinically meaningful earlier diagnosis.",
        "subclaim_type": "existence",
        "scope": "Asymptomatic age at least 50; assay version and diagnostic confirmation specified",
        "claimed_scope": "Asymptomatic age at least 50; assay version and diagnostic confirmation specified",
        "governing_rubric": "02-cancer-biology.md",
        "key_evidence_anchor": "Prospective detection and false-positive follow-up",
        "hsef_level": "Γ",
        "confidence": "High",
        "governing_cap_or_threshold": "Quoted boundary and upward audit below.",
        "rationale": "Prospective Galleri studies and the NHS intervention-arm performance report demonstrate genuine cancer detections with quantified false positives, missed cancers and tissue-origin guidance. Diagnostic accuracy is reported descriptively, not as a causal grade on whether detection exists. The helper-compatible Γ entry records the unbridged inference from that diagnostic signal to meaningful clinical benefit, not doubt that the test detects some cancers. Case-control sensitivity differs from screening performance and cannot be substituted into population benefit estimates.",
        "rubric_adaptation": "Diagnostic observations are described with actual denominators and ascertainment. The accompanying Γ is only the unestablished causal translation to clinical benefit; it is not a rating that detection or analytical validity is mechanistically uncertain."
      },
      {
        "id": "SC2",
        "statement": "Adding screening reduces cancer mortality compared with usual care.",
        "subclaim_type": "sufficiency",
        "scope": "Asymptomatic age at least 50; randomized allocation and adequate outcome horizon",
        "claimed_scope": "Asymptomatic age at least 50; randomized allocation and adequate outcome horizon",
        "governing_rubric": "02-cancer-biology.md",
        "key_evidence_anchor": "Mortality-based screening trials",
        "hsef_level": "Γ",
        "confidence": "High",
        "governing_cap_or_threshold": "Quoted boundary and upward audit below.",
        "rationale": "No examined primary report provides a positive randomized Galleri cancer-mortality contrast. The 2026 NHS trial randomized 142250 adults aged 50–77; its primary stage III/IV endpoint was null, while the stage IV secondary contrast was favorable. These are stage endpoints, not deaths. Official trial information states that mortality follow-up continues; the trial was not powered for mortality endpoints. Detection, feasibility, reported treatment and favorable stage subsets cannot cross the registered mortality threshold. Γ reflects plausible partial clinical system support with an unverified mortality bridge, not proof that a mortality trial has refuted Galleri.",
        "rubric_adaptation": "The field-valid screening equivalent is a randomized offer/addition of the exact Galleri pathway versus usual care in baseline asymptomatic adults≥50, with retained standard screening and adequately powered cancer-mortality follow-up. Stage and detection endpoints do not supply that death endpoint."
      },
      {
        "id": "SC3",
        "statement": "A favorable stage shift establishes mortality benefit.",
        "subclaim_type": "mechanism",
        "scope": "Lead time, length bias and overdiagnosis considered; disease site prespecified",
        "claimed_scope": "Lead time, length bias and overdiagnosis considered; disease site prespecified",
        "governing_rubric": "02-cancer-biology.md",
        "key_evidence_anchor": "Stage-to-mortality validation and randomized follow-up",
        "hsef_level": "Γ",
        "confidence": "High",
        "governing_cap_or_threshold": "Quoted boundary and upward audit below.",
        "rationale": "A stage shift is insufficient by itself to establish saved lives. UKCTOCS directly demonstrates more stage I and fewer stage IV ovarian/tubal diagnoses without a cancer-mortality reduction after 16.3 years. Across 41 screening RCTs, late-stage incidence reductions tracked mortality closely for ovarian and lung cancer but weakly for colorectal and prostate cancer (PMID38583868); UKCTOCS's combined stage III/IV change was not significant, so its dissociation is a stage IV-only one, the same pattern as NHS-Galleri. NHS-Galleri's stage IV secondary signal is retained, but the combined stage III/IV primary endpoint was not met. Site-specific biology, lead time, overdiagnosis, treatment and competing mortality require direct validation; stage-to-mortality causal inference retains Γ.",
        "rubric_adaptation": "A stage surrogate must predict intervention-caused mortality change across prespecified cancer sites, assays and treatment contexts. Prognostic stage-survival associations and longer survival measured from earlier diagnosis are not surrogate validation."
      },
      {
        "id": "SC4",
        "statement": "Full-body MRI and direct-to-consumer testing provide comparable net clinical screening benefit.",
        "subclaim_type": "generalization",
        "scope": "Exact test and population; downstream procedures, harms and mortality",
        "claimed_scope": "Exact test and population; downstream procedures, harms and mortality",
        "governing_rubric": "02-cancer-biology.md",
        "key_evidence_anchor": "Test-specific clinical benefit-harm comparisons",
        "hsef_level": "Α",
        "confidence": "Moderate",
        "governing_cap_or_threshold": "Quoted boundary and upward audit below.",
        "rationale": "General-population full-body MRI and DTC testing lack a verified comparable net mortality benefit in the examined sources. MRI detects real lesions and some cancers, while incidental findings, investigations, costs and distress also occur. Hereditary TP53 surveillance and abnormal prenatal cfDNA workup are enriched contexts and different packages. A selected DTC confirmation series identifies false variants without implying40% of all consumer tests are wrong. Blanket clinical-benefit equivalence remains Α.",
        "rubric_adaptation": "Each commercial MRI or DTC test requires its own defined population, diagnostic pathway, mortality/function endpoints and harm assessment. High-risk syndrome surveillance, risk genotyping and average-risk occult-cancer screening are different propositions."
      }
    ],
    "aggregation_rule": "primary-subclaim",
    "aggregation_preregistered": true,
    "aggregation_rationale": "The precise lead clinical proposition is SC2. Mechanism, competing-cause, generalization and safety companions remain separately reported; they do not replace the primary clinical endpoint.",
    "primary_subclaim_id": "SC2",
    "aggregation_derivation": "The preregistered primary-subclaim rule returns Γ from SC2. Fifty-eight original reports were examined, covering Galleri/other MCED diagnostic work, prospective implementation, real mortality-based single-cancer screening comparators, and separate MRI/DTC pathways. No positive Galleri mortality crossing is counted. The current primary stage endpoint failed and a favorable secondary stage IV signal remains; neither proves a mortality benefit or a mortality null. Weakest-link returns Α from the broad companion claim, while primary-subclaim and scope-matched return Γ. The review preserves genuine detections and legitimate established screening benefits without assigning them to a different assay.",
    "aggregation_alternatives": {
      "weakest_link_would_return": "Α",
      "primary_subclaim_would_return": "Γ",
      "scope_matched_would_return": "Γ",
      "note": "Separate narrow successes do not replace the preregistered full-scope gate."
    },
    "index_rule_deviation": ""
  },
  "competing_models": {
    "models_evaluated": [
      {
        "rank_in_tournament": 1,
        "model_id": "M4",
        "is_nominal": false,
        "name": "Screening benefit is site, assay, risk and pathway specific",
        "core_claim": "Earlier detection can reduce mortality in defined screening programmes, while other apparently favorable diagnostic or stage programmes do not.",
        "explains_what_nominal_does_not": "Earlier detection can reduce mortality in defined screening programmes, while other apparently favorable diagnostic or stage programmes do not.",
        "strongest_supporting_evidence": [
          "NLST and NELSON show positive randomized lung-mortality effects in high-risk smokers (PMID21714641,31995683); UKCTOCS shows a long-term ovarian stage IV/mortality dissociation, with a non-significant combined stage III/IV change (PMID33991479); across 41 screening RCTs, reductions in late-stage incidence tracked mortality reductions closely for ovarian and lung cancer but weakly for colorectal and prostate cancer (PMID38583868). Galleri sensitivity varies by burden and site (PMID34176681,42773209)."
        ],
        "strongest_contradictory_evidence": [
          "This establishes contextual screening causality, not a positive Galleri mortality result. It does not identify a universal stage surrogate or a superior test for every cancer."
        ],
        "hsef_level_for_this_model": "Ε",
        "rationale": "NLST and NELSON show positive randomized lung-mortality effects in high-risk smokers (PMID21714641,31995683); UKCTOCS shows a long-term ovarian stage IV/mortality dissociation, with a non-significant combined stage III/IV change (PMID33991479); across 41 screening RCTs, reductions in late-stage incidence tracked mortality reductions closely for ovarian and lung cancer but weakly for colorectal and prostate cancer (PMID38583868). Galleri sensitivity varies by burden and site (PMID34176681,42773209). This establishes contextual screening causality, not a positive Galleri mortality result. It does not identify a universal stage surrogate or a superior test for every cancer."
      },
      {
        "rank_in_tournament": 2,
        "model_id": "M3",
        "is_nominal": false,
        "name": "Diagnostic cascades and overdiagnosis alter net benefit",
        "core_claim": "Broad screening produces real detections and additional diagnostic work, with a net balance that can differ from analytical accuracy.",
        "explains_what_nominal_does_not": "Broad screening produces real detections and additional diagnostic work, with a net balance that can differ from analytical accuracy.",
        "strongest_supporting_evidence": [
          "PATHFINDER false-positive resolution/workup (PMID37805216), UKCTOCS unnecessary surgery (PMID37183782), SHIP biopsy/cost findings (PMID32860149,34996801) and DTC confirmation errors (PMID29565420) document relevant burdens."
        ],
        "strongest_contradictory_evidence": [
          "Overdiagnosis is not directly quantified by every incidental finding, and higher costs or biopsies do not alone prove net harm. Observational MRI attribution and lack of exact Galleri mortality follow-up limit clinical balance claims."
        ],
        "hsef_level_for_this_model": "Γ",
        "rationale": "PATHFINDER false-positive resolution/workup (PMID37805216), UKCTOCS unnecessary surgery (PMID37183782), SHIP biopsy/cost findings (PMID32860149,34996801) and DTC confirmation errors (PMID29565420) document relevant burdens. Overdiagnosis is not directly quantified by every incidental finding, and higher costs or biopsies do not alone prove net harm. Observational MRI attribution and lack of exact Galleri mortality follow-up limit clinical balance claims."
      },
      {
        "rank_in_tournament": 3,
        "model_id": "M2",
        "is_nominal": false,
        "name": "Lead time, length selection and incomplete ascertainment inflate survival narratives",
        "core_claim": "Longer survival from diagnosis or favorable detected-cancer series can arise without moving the actual time of death.",
        "explains_what_nominal_does_not": "Longer survival from diagnosis or favorable detected-cancer series can arise without moving the actual time of death.",
        "strongest_supporting_evidence": [
          "UKCTOCS separates a stage IV reduction, with a non-significant combined stage III/IV change, from deaths (PMID33991479); real-world Galleri has45% positive follow-up and lacks systematic negative follow-up (PMID41173830). Prediagnostic PanSeer/ARIC results show a potential observation interval, not intervention-caused saved lives (PMID32694610,40402478)."
        ],
        "strongest_contradictory_evidence": [
          "These biases are plausible source-specific limits rather than proof that every earlier diagnosis is useless or that aggressive cfDNA-detected cancers are all indolent. Randomized site-specific mortality benefits remain real."
        ],
        "hsef_level_for_this_model": "Γ",
        "rationale": "UKCTOCS separates a stage IV reduction, with a non-significant combined stage III/IV change, from deaths (PMID33991479); real-world Galleri has45% positive follow-up and lacks systematic negative follow-up (PMID41173830). Prediagnostic PanSeer/ARIC results show a potential observation interval, not intervention-caused saved lives (PMID32694610,40402478). These biases are plausible source-specific limits rather than proof that every earlier diagnosis is useless or that aggressive cfDNA-detected cancers are all indolent. Randomized site-specific mortality benefits remain real."
      },
      {
        "rank_in_tournament": 4,
        "model_id": "M1",
        "is_nominal": true,
        "name": "Galleri addition reduces cancer mortality",
        "core_claim": "Adding specified Galleri screening to usual care causes fewer cancer deaths in baseline asymptomatic adults≥50.",
        "explains_what_nominal_does_not": "Adding specified Galleri screening to usual care causes fewer cancer deaths in baseline asymptomatic adults≥50.",
        "strongest_supporting_evidence": [
          "True prospective cancers, tissue-origin guidance and a favorable stageIV secondary contrast support clinical plausibility (PMID37805216,42773209,42776074)."
        ],
        "strongest_contradictory_evidence": [
          "No positive randomized death endpoint is reported in the examined sources; the combined stageIII/IV primary endpoint was null. Separate screening programmes or survival simulations cannot supply exact-assay mortality proof."
        ],
        "hsef_level_for_this_model": "Γ",
        "rationale": "True prospective cancers, tissue-origin guidance and a favorable stageIV secondary contrast support clinical plausibility (PMID37805216,42773209,42776074). No positive randomized death endpoint is reported in the examined sources; the combined stageIII/IV primary endpoint was null. Separate screening programmes or survival simulations cannot supply exact-assay mortality proof."
      },
      {
        "rank_in_tournament": 5,
        "model_id": "M5",
        "is_nominal": false,
        "name": "Shedding-biased detection",
        "core_claim": "CfDNA tests preferentially detect high-shedding, biologically advanced cancers, so detections concentrate where an earlier diagnosis changes outcomes least.",
        "explains_what_nominal_does_not": "Why detected cancers can concentrate in advanced, high-shedding disease, and why a stage IV decrease can be offset by more stage III cancers without a fatal-cancer reduction.",
        "strongest_supporting_evidence": [
          "CCGA validation sensitivity rose from 16.8% in stage I to 90.1% in stage IV (PMID34176681); NHS all-cancer episode sensitivity was 26.7–37.2% (PMID42773209); tumor-fraction correlates link detection to tumor burden and aggressiveness (PMID34432811); and in NHS-Galleri the stage IV decrease was offset by more stage III cancers (PMID42776074)."
        ],
        "strongest_contradictory_evidence": [
          "Preferential detection of advanced disease does not show that every detected cancer would be untreatable or that earlier detection never helps; the mortality consequence is untested. Added after the 2026-11-02 adversarial review (finding S10) and appended without re-ranking the original tournament."
        ],
        "hsef_level_for_this_model": "Γ",
        "rationale": "CCGA validation sensitivity rose from 16.8% in stage I to 90.1% in stage IV (PMID34176681); NHS all-cancer episode sensitivity was 26.7–37.2% (PMID42773209); tumor-fraction correlates link detection to tumor burden and aggressiveness (PMID34432811); and in NHS-Galleri the stage IV decrease was offset by more stage III cancers (PMID42776074). Preferential detection of advanced disease does not show that every detected cancer would be untreatable or that earlier detection never helps; the mortality consequence is untested. Added after the 2026-11-02 adversarial review (finding S10) and appended without re-ranking the original tournament.",
        "added": "2026-11-02, adversarial finding S10; appended without re-ranking ranks 1-4"
      }
    ],
    "tournament_summary": "Descriptive comparison; does not modify the nominal score. UKCTOCS's original randomized long-term report (PMID33991479) separates a context-specific clinical screening model from an assumption that favorable stage movement universally establishes saved lives: stageIV fell while ovarian/tubal mortality did not. Positive NLST/NELSON mortality findings preserve the possibility of genuine screening benefit. This comparator does not decide Galleri's eventual mortality result.",
    "study_separating_rank1_from_rank2": "UKCTOCS's original randomized long-term report (PMID33991479) separates a context-specific clinical screening model from an assumption that favorable stage movement universally establishes saved lives: stageIV fell while ovarian/tubal mortality did not. Positive NLST/NELSON mortality findings preserve the possibility of genuine screening benefit. This comparator does not decide Galleri's eventual mortality result.",
    "nominal_wins_only_by_funding_artifact": false,
    "level_unchanged_by_tournament": true
  },
  "evidence_inventory": [
    {
      "n": 1,
      "pmid": "42776074",
      "title": "Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis.",
      "citation": "Sasieni P, Johnson P, Round T et al. Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis. The New England journal of medicine. 2026.",
      "doi": "10.1056/NEJMoa2505723",
      "pmcid": "PMC7619610",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42776074/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42776074/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "NHS_Galleri_NCT05611632",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Adversarial pass 2026-11-02 examined the PMC author manuscript (PMC7619610) for secondary-endpoint testing status, stage III and IV counts, the fatal-cancer composite and the mortality-power statement.",
      "relates_to_subclaims": [
        "SC1",
        "SC2",
        "SC3"
      ],
      "favors_models": [
        "M4"
      ],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "mixed",
      "what_it_shows": "NHS-Galleri randomized 142250 adults 50–77 to tested versus stored blood plus usual care for 3 annual rounds; primary stage III/IV incidence IRR 1.03, 95% CI 0.92–1.14, P=.63; key secondary stage IV IRR 0.86, 95% CI 0.74–1.00, not formally tested under the fixed-sequence plan and with an unadjusted interval; the stage IV decrease (341 vs 394) was offset by more stage III cancers (360 vs 287), and the secondary stage III/IV-or-fatal composite was null (IRR 1.04, 0.97–1.12; PMC7619610).",
      "what_it_does_not_show": "Primary proxy failed, secondary signal retained; no mortality result in this publication. Neither randomized design nor a stage IV contrast supplies a positive cancer-mortality crossing. Publisher abstract verified 22 September 2026; full-body access not claimed.",
      "confounders_present": [
        "Primary proxy failed, secondary signal retained; no mortality result in this publication. Neither randomized design nor a stage IV contrast supplies a positive cancer-mortality crossing. Publisher abstract verified 22 September 2026; full-body access not claimed."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": true,
      "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.",
      "shared_components": []
    },
    {
      "n": 2,
      "pmid": "42773209",
      "title": "Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial.",
      "citation": "Neal RD, Dolly S, Johnson P et al. Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial. Nature medicine. 2026.",
      "doi": "10.1038/s41591-026-04652-8",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42773209/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42773209/",
      "tier": "A",
      "source_tier": "A",
      "kind": "secondary_trial_diagnostic_report",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "NHS_Galleri_NCT05611632",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC2"
      ],
      "favors_models": [
        "M4"
      ],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": true,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "Same NHS trial descriptive test-performance report across3rounds:937detectedprimary cancers, PPV58.0/50.4/45.8%, all-cancer episode sensitivity26.7–37.2%, specificity99.5–99.6%.",
      "what_it_does_not_show": "Descriptive intervention-arm diagnosis metrics without hypothesis testing; not an independent randomized trial or mortality analysis. High NPV largely reflects low prevalence and does not mean every cancer is excluded.",
      "confounders_present": [
        "Descriptive intervention-arm diagnosis metrics without hypothesis testing; not an independent randomized trial or mortality analysis. High NPV largely reflects low prevalence and does not mean every cancer is excluded."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.",
      "shared_components": [
        "Descriptive test performance in the intervention arm of the same randomized NHS parent."
      ]
    },
    {
      "n": 3,
      "pmid": "39862108",
      "title": "NHS-Galleri trial: Enriched enrolment approaches and sociodemographic characteristics of enrolled participants.",
      "citation": "Swanton C, Bachtiar V, Mathews C et al. NHS-Galleri trial: Enriched enrolment approaches and sociodemographic characteristics of enrolled participants. Clinical trials (London, England). 2025.",
      "doi": "10.1177/17407745241302477",
      "pmcid": "PMC11986080",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39862108/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39862108/",
      "tier": "A",
      "source_tier": "A",
      "kind": "original_trial_enrollment_analysis",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "NHS_Galleri_NCT05611632",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC2"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "Original NHS recruitment analysis1.5million invitations/142924 enrolled; older/deprived groups enriched but Black/Asian groups underrepresented despite targeting.",
      "what_it_does_not_show": "Same parent trial, recruitment denominators differ from final randomized142250. Sociodemographic reach does not establish efficacy, and enrollment composition limits transportability.",
      "confounders_present": [
        "Same parent trial, recruitment denominators differ from final randomized142250. Sociodemographic reach does not establish efficacy, and enrollment composition limits transportability."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": [
        "Recruitment denominator142924 differs from final randomized142250, not a separate trial."
      ]
    },
    {
      "n": 4,
      "pmid": "40406252",
      "title": "Clinical referral to the NHS following multi-cancer early detection test results from the NHS-Galleri trial.",
      "citation": "Lowenhoff I, Dolly S, Dowinton Smith R et al. Clinical referral to the NHS following multi-cancer early detection test results from the NHS-Galleri trial. Frontiers in oncology. 2025.",
      "doi": "10.3389/fonc.2025.1511816",
      "pmcid": "PMC12096138",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40406252/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40406252/",
      "tier": "A",
      "source_tier": "A",
      "kind": "original_implementation_report",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "NHS_Galleri_NCT05611632",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC2"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "Original NHS operational report describes nurse referral into56Trusts with CSO-guided pathways and safety-netting.",
      "what_it_does_not_show": "Implementation feasibility and coordination are meaningful but not mortality benefit, diagnostic accuracy estimates or a separate efficacy trial.",
      "confounders_present": [
        "Implementation feasibility and coordination are meaningful but not mortality benefit, diagnostic accuracy estimates or a separate efficacy trial."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 5,
      "pmid": "33506766",
      "title": "Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.",
      "citation": "Liu MC, Oxnard GR, Klein EA et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Annals of oncology : official journal of the European Society for Medical Oncology. 2020.",
      "doi": "10.1016/j.annonc.2020.02.011",
      "pmcid": "PMC8274402",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33506766/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33506766/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "CCGA_STRIVE_assay_development",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC3"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "CCGA/STRIVE case-control training/validation cfDNA methylation; specificity99.3%, all-cancer stageI sensitivity18% rising to93%stageIV.",
      "what_it_does_not_show": "Known-cancer versus control design and version differ from population screening; sensitivity increases with burden. Detection feasibility does not validate stage-to-mortality benefit.",
      "confounders_present": [
        "Known-cancer versus control design and version differ from population screening; sensitivity increases with burden. Detection feasibility does not validate stage-to-mortality benefit."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 6,
      "pmid": "34176681",
      "title": "Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.",
      "citation": "Klein EA, Richards D, Cohn A et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Annals of oncology : official journal of the European Society for Medical Oncology. 2021.",
      "doi": "10.1016/j.annonc.2021.05.806",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34176681/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34176681/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "CCGA3_NCT02889978",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC3"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "CCGA independent validation4077 participants including2823known cancers; specificity99.5%, overall sensitivity51.5%, stageI16.8%, tissueorigin88.7%.",
      "what_it_does_not_show": "Case-control spectrum/prevalence differs from asymptomatic screening; independent validation set is not an independent mortality perturbation. Stage-specific sensitivity is descriptive.",
      "confounders_present": [
        "Case-control spectrum/prevalence differs from asymptomatic screening; independent validation set is not an independent mortality perturbation. Stage-specific sensitivity is descriptive."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 7,
      "pmid": "36400018",
      "title": "Evaluation of cell-free DNA approaches for multi-cancer early detection.",
      "citation": "Jamshidi A, Liu MC, Klein EA et al. Evaluation of cell-free DNA approaches for multi-cancer early detection. Cancer cell. 2022.",
      "doi": "10.1016/j.ccell.2022.10.022",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36400018/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36400018/",
      "tier": "A",
      "source_tier": "A",
      "kind": "original_assay_comparison",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "CCGA1_NCT02889978",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "CCGA1 compares10cfDNA classifiers at98%specificity; tumor allele fraction predicts detection and methylation localizes origin.",
      "what_it_does_not_show": "Same assay-development samples; classifier optimization and limit of detection do not show clinical utility, treatment benefit or prospective-screening accuracy.",
      "confounders_present": [
        "Same assay-development samples; classifier optimization and limit of detection do not show clinical utility, treatment benefit or prospective-screening accuracy."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 8,
      "pmid": "34432811",
      "title": "Clinical correlates of circulating cell-free DNA tumor fraction.",
      "citation": "Bredno J, Lipson J, Venn O et al. Clinical correlates of circulating cell-free DNA tumor fraction. PloS one. 2021.",
      "doi": "10.1371/journal.pone.0256436",
      "pmcid": "PMC8386888",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34432811/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34432811/",
      "tier": "A",
      "source_tier": "A",
      "kind": "original_tumor_fraction_analysis",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "CCGA1_and2_NCT02889978",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC3"
      ],
      "favors_models": [
        "M4"
      ],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "CCGA tumor-fraction models relate breast/lung tumor mitotic or metabolic volume and colorectal invasion to cfDNA and validate inCCGA2.",
      "what_it_does_not_show": "Biological correlation may explain preferential detection of aggressive cancers; it does not establish that detected cancers are treatable earlier or that overdiagnosis is absent.",
      "confounders_present": [
        "Biological correlation may explain preferential detection of aggressive cancers; it does not establish that detected cancers are treatable earlier or that overdiagnosis is absent."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 9,
      "pmid": "36495927",
      "title": "Performance of a targeted methylation-based multi-cancer early detection test by race and ethnicity.",
      "citation": "Tang WHW, Yimer H, Tummala M et al. Performance of a targeted methylation-based multi-cancer early detection test by race and ethnicity. Preventive medicine. 2023.",
      "doi": "10.1016/j.ypmed.2022.107384",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36495927/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36495927/",
      "tier": "A",
      "source_tier": "A",
      "kind": "secondary_diagnostic_subgroup_analysis",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "CCGA3_NCT02889978",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "CCGA3 descriptive racial/ethnic analysis uses same4077validation participants; specificity high across groups with some small subgroup samples.",
      "what_it_does_not_show": "Exploratory subgroup intervals and predominantlyWhite cohort limit broad equivalence claims; no independent efficacy trial or mortality result.",
      "confounders_present": [
        "Exploratory subgroup intervals and predominantlyWhite cohort limit broad equivalence claims; no independent efficacy trial or mortality result."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": [
        "Same4077 CCGA3 validation set; racial/ethnic strata do not create new efficacy trials."
      ]
    },
    {
      "n": 10,
      "pmid": "37805216",
      "title": "Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study.",
      "citation": "Schrag D, Beer TM, McDonnell CH et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet (London, England). 2023.",
      "doi": "10.1016/S0140-6736(23)01700-2",
      "pmcid": "PMC11027492",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37805216/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37805216/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PATHFINDER_NCT04241796",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC2",
        "SC4"
      ],
      "favors_models": [
        "M3"
      ],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": true,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "PATHFINDER convenience cohort≥50 without cancer symptoms:6621 analyzable;92signals,35confirmed,57falsepositives; false-positive diagnostic resolution median162days and30%procedures.",
      "what_it_does_not_show": "Single-arm feasibility primary endpoint is diagnostic workup, not mortality. A low overall false-positive rate and62%false-positive share among signals are different denominators. Attempted originalXML returned500; abstract examined.",
      "confounders_present": [
        "Single-arm feasibility primary endpoint is diagnostic workup, not mortality. A low overall false-positive rate and62%false-positive share among signals are different denominators. Attempted originalXML returned500; abstract examined."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.",
      "shared_components": []
    },
    {
      "n": 11,
      "pmid": "32345712",
      "title": "Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention.",
      "citation": "Lennon AM, Buchanan AH, Kinde I et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science (New York, N.Y.). 2020.",
      "doi": "10.1126/science.abb9601",
      "pmcid": "PMC7509949",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32345712/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32345712/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID32345712",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC2",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "mixed",
      "what_it_shows": "DETECT-A prospective blood-test/PETCT pathway10006women found26cancers by blood;24 by routine screening and46neither;0.22%futile invasive procedures.",
      "what_it_does_not_show": "Different assay plusPETCT package, no randomized mortality control. Curative-intent surgery is not proven cure or mortality reduction; routine screening remains complementary. PublicXML failed500.",
      "confounders_present": [
        "Different assay plusPETCT package, no randomized mortality control. Curative-intent surgery is not proven cure or mortality reduction; routine screening remains complementary. PublicXML failed500."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 12,
      "pmid": "40425843",
      "title": "Early detection of multiple cancer types using multidimensional cell-free DNA fragmentomics.",
      "citation": "Bao H, Yang S, Chen X et al. Early detection of multiple cancer types using multidimensional cell-free DNA fragmentomics. Nature medicine. 2025.",
      "doi": "10.1038/s41591-025-03735-2",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40425843/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40425843/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID40425843",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "Alternative fragmentomics assay validated in separate known-cancer cohorts and preliminary3724asymptomatic cohort with53.5%sensitivity/98.1%specificity.",
      "what_it_does_not_show": "Not Galleri; case-control high sensitivity falls in screening context. Clinical decision potential and cancer detection do not prove survival benefit.",
      "confounders_present": [
        "Not Galleri; case-control high sensitivity falls in screening context. Clinical decision potential and cancer detection do not prove survival benefit."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 13,
      "pmid": "37698949",
      "title": "Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker.",
      "citation": "Taylor MS, Wu C, Fridy PC et al. Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker. Cancer discovery. 2023.",
      "doi": "10.1158/2159-8290.CD-23-0313",
      "pmcid": "PMC10773488",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37698949/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37698949/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "UpdateOf: PMID36747644",
        "ErratumIn: PMID39228301"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID37698949",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "ORF1p ultrasensitive plasma protein assay identifies multicancer and precursor signals, with prognostic associations and response monitoring.",
      "what_it_does_not_show": "Alternative biomarker, not Galleri or randomized early detection. Original correction39228301 restores a compositor-omitted ovarian tissue-expression pie chart in Fig1D; no changed detection result is specified. Biomarker detection is not a mortality crossing.",
      "confounders_present": [
        "Alternative biomarker, not Galleri or randomized early detection. Original correction39228301 restores a compositor-omitted ovarian tissue-expression pie chart in Fig1D; no changed detection result is specified. Biomarker detection is not a mortality crossing."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 14,
      "pmid": "36849097",
      "title": "Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies.",
      "citation": "Gao Q, Lin YP, Li BS et al. Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies. Annals of oncology : official journal of the European Society for Medical Oncology. 2023.",
      "doi": "10.1016/j.annonc.2023.02.010",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36849097/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36849097/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID36849097",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC3"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "THUNDER original case-control independent505cancer/505control validation of6cancer methylation panel showed69.1%sensitivity/98.9%specificity.",
      "what_it_does_not_show": "Predicted late-stage decline and survival gains are simulations, not observed intervention outcomes; new original diagnostic component alone earns report credit. Assay differs from Galleri.",
      "confounders_present": [
        "Predicted late-stage decline and survival gains are simulations, not observed intervention outcomes; new original diagnostic component alone earns report credit. Assay differs from Galleri."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": [
        "Only original diagnostic validation earns primary-report credit; simulated stage/survival results earn no observed causal threshold credit."
      ]
    },
    {
      "n": 15,
      "pmid": "40934080",
      "title": "Phosphatidylserine-positive extracellular vesicles for detecting multiple operable cancers.",
      "citation": "Jin F, Yang P, Xu R et al. Phosphatidylserine-positive extracellular vesicles for detecting multiple operable cancers. Cell reports. 2025.",
      "doi": "10.1016/j.celrep.2025.116259",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40934080/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40934080/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID40934080",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "AlternativePSpositive vesicle assay1869clinical samples and3validation cohorts; early-stage sensitivity74.7% with89.8%specificity; cells/mice support marker biology.",
      "what_it_does_not_show": "Known-cancer cohort spectrum and relativelylower specificity may matter at lowprevalence; no Galleri inference, asymptomatic mortalitytrial or demonstrated curative benefit.",
      "confounders_present": [
        "Known-cancer cohort spectrum and relativelylower specificity may matter at lowprevalence; no Galleri inference, asymptomatic mortalitytrial or demonstrated curative benefit."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 16,
      "pmid": "40402478",
      "title": "Detection of Cancers Three Years prior to Diagnosis Using Plasma Cell-Free DNA.",
      "citation": "Wang Y, Joshu CE, Curtis SD et al. Detection of Cancers Three Years prior to Diagnosis Using Plasma Cell-Free DNA. Cancer discovery. 2025.",
      "doi": "10.1158/2159-8290.CD-25-0375",
      "pmcid": "PMC12354160",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40402478/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40402478/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID40402478",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC3"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "ARIC26cases/26controls with storedserialplasma;4of6assessable earlier samples contained same mutations3.1–3.5years before diagnosis at muchlowerfraction.",
      "what_it_does_not_show": "Verysmall nested case-control detection benchmark; retrospective earlier-sample interrogation is not prospective clinical intervention or proof that years-earlier treatment prevents death.",
      "confounders_present": [
        "Verysmall nested case-control detection benchmark; retrospective earlier-sample interrogation is not prospective clinical intervention or proof that years-earlier treatment prevents death."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 17,
      "pmid": "40737714",
      "title": "Pan-cancer methylation analysis of circulating cell-free DNA.",
      "citation": "Dong W, Lau CH, Li J et al. Pan-cancer methylation analysis of circulating cell-free DNA. Cancer genetics. 2025.",
      "doi": "10.1016/j.cancergen.2025.07.014",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40737714/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40737714/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID40737714",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC2"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "AlternativePCRmethylation panel103diverse cancer cases/40healthy controls showed47.6%sensitivity/90%specificity.",
      "what_it_does_not_show": "Background sentence asserting all-cause mortality reduction is not a study result; no mortality endpoint or population screening. Small proof-of-concept rather than Galleri validation.",
      "confounders_present": [
        "Background sentence asserting all-cause mortality reduction is not a study result; no mortality endpoint or population screening. Small proof-of-concept rather than Galleri validation."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 18,
      "pmid": "41173830",
      "title": "Real-world data and clinical experience from over 100,000 multi-cancer early detection tests.",
      "citation": "Matrana M, Shukla V, Kingsbury D et al. Real-world data and clinical experience from over 100,000 multi-cancer early detection tests. Nature communications. 2025.",
      "doi": "10.1038/s41467-025-64094-7",
      "pmcid": "PMC12578847",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41173830/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41173830/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID41173830",
      "access_depth": "full_text_partial",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Results:paragraph5, 1:Results:paragraph6, 1:Results:paragraph12, 1:Results:paragraph13, 3:Methods:paragraph1, 3:Methods:paragraph2, 3:Methods:paragraph3, 3:Methods:paragraph4. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC2"
      ],
      "favors_models": [
        "M2",
        "M4"
      ],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": true,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "OriginalM/R:111080real-world tests≥22,1011signals;voluntary outcomes459,48ongoingworkups,411complete. Asymptomatic completed subset128/259invasive cancers, ePPV49.4%; negatives not systematically followed.",
      "what_it_does_not_show": "Symptomatic/active-cancer uses and incompletepositive follow-up preclude fullpopulation sensitivity, universalPPV or mortality claims. Large testcount is not completeclinical ascertainment or screening-only cohort.",
      "confounders_present": [
        "Symptomatic/active-cancer uses and incompletepositive follow-up preclude fullpopulation sensitivity, universalPPV or mortality claims. Large testcount is not completeclinical ascertainment or screening-only cohort."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.",
      "shared_components": []
    },
    {
      "n": 19,
      "pmid": "37819044",
      "title": "Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization.",
      "citation": "Nguyen VTC, Nguyen TH, Doan NNT et al. Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization. eLife. 2023.",
      "doi": "10.7554/eLife.89083",
      "pmcid": "PMC10567114",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37819044/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37819044/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "UpdateOf: PMID not supplied",
        "UpdateOf: PMID not supplied",
        "UpdateOf: PMID not supplied"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "SPOTMAS_case_control_development",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "SPOTMAS methylomics/fragmentomics738nonmetastatic cancercases/1550healthy controls;72.4%sensitivity at97%specificity; stage-dependent results.",
      "what_it_does_not_show": "Alternative assay case-control training/validation, not population predictivevalues or mortality benefit. UpdateOf notices carry no suppliedPMIDs and are retained as version-history uncertainty.",
      "confounders_present": [
        "Alternative assay case-control training/validation, not population predictivevalues or mortality benefit. UpdateOf notices carry no suppliedPMIDs and are retained as version-history uncertainty."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 20,
      "pmid": "39620930",
      "title": "Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons.",
      "citation": "Michel M, Heidary M, Mechri A et al. Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025.",
      "doi": "10.1158/1078-0432.CCR-24-2669",
      "pmcid": "PMC11959274",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39620930/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39620930/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID39620930",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "LINE1 hypomethylation classifiers747samples in2independent cohorts distinguish6cancer plasmas withhighAUC.",
      "what_it_does_not_show": "Different reference-free assay; AUC across selectedclinical cohorts is not lowprevalence screeningPPV or clinicalmortality benefit.",
      "confounders_present": [
        "Different reference-free assay; AUC across selectedclinical cohorts is not lowprevalence screeningPPV or clinicalmortality benefit."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 21,
      "pmid": "39333750",
      "title": "Noninvasive multi-cancer detection using blood-based cell-free microRNAs.",
      "citation": "Zhang J, Rui H, Hu H. Noninvasive multi-cancer detection using blood-based cell-free microRNAs. Scientific reports. 2024.",
      "doi": "10.1038/s41598-024-73783-0",
      "pmcid": "PMC11436735",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39333750/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39333750/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID39333750",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "SerummiRNA training2800plus and independentlarge case-controlvalidation yields veryhigh reportedsite-specific sensitivity/specificity.",
      "what_it_does_not_show": "Platform, batch/spectrum and control selection needprospective transportability checks; independent assay validation is not assignedscreening benefit or Galleri performance.",
      "confounders_present": [
        "Platform, batch/spectrum and control selection needprospective transportability checks; independent assay validation is not assignedscreening benefit or Galleri performance."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 22,
      "pmid": "41495807",
      "title": "Detection of primary cancer types via fragment size selection in circulating cell-free extrachromosomal circular DNA.",
      "citation": "Fang J, Luo S, Li S et al. Detection of primary cancer types via fragment size selection in circulating cell-free extrachromosomal circular DNA. Genome medicine. 2026.",
      "doi": "10.1186/s13073-025-01595-6",
      "pmcid": "PMC12870451",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41495807/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41495807/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID41495807",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "413cancer/239healthy plasmaeccDNA data plusPDXfragment model trainScanTecc; cancerclassificationAUC.92 andoriginAUC.79.",
      "what_it_does_not_show": "Exploratory assay andin-silicofragment selection cannot establish clinicalutility, populationPPV or benefit; PDXmechanism does not supplyscreeningmortality evidence.",
      "confounders_present": [
        "Exploratory assay andin-silicofragment selection cannot establish clinicalutility, populationPPV or benefit; PDXmechanism does not supplyscreeningmortality evidence."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 23,
      "pmid": "36469776",
      "title": "Noninvasive detection of any-stage cancer using free glycosaminoglycans.",
      "citation": "Bratulic S, Limeta A, Dabestani S et al. Noninvasive detection of any-stage cancer using free glycosaminoglycans. Proceedings of the National Academy of Sciences of the United States of America. 2022.",
      "doi": "10.1073/pnas.2115328119",
      "pmcid": "PMC9897435",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36469776/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36469776/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID36469776",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC3"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "FreeGAGprofiles original1260subjects andvalidation screening-like121/49cases showlower firststage detection at≥99%specificity; undetectedcancers havebetter prognosis.",
      "what_it_does_not_show": "Detection correlateswith risk but doesnot show screening reduces deaths; prognostic selection and known-case sampling constrain survival claims. Alternativeassay notGalleri.",
      "confounders_present": [
        "Detection correlateswith risk but doesnot show screening reduces deaths; prognostic selection and known-case sampling constrain survival claims. Alternativeassay notGalleri."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 24,
      "pmid": "40317486",
      "title": "Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test.",
      "citation": "Brito-Rocha T, Constâncio V, Leite-Silva P et al. Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test. International journal of cancer. 2025.",
      "doi": "10.1002/ijc.35467",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40317486/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40317486/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID40317486",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "NovelddPCR promoterpanel485plasmas andtissuedata achieves60.1%sensitivity/87.4%specificity across4majorcancers.",
      "what_it_does_not_show": "Lowprevalence falsepositive implications, smallproof-of-concept andotherassay identity limit population screening; no clinicaldeathendpoint.",
      "confounders_present": [
        "Lowprevalence falsepositive implications, smallproof-of-concept andotherassay identity limit population screening; no clinicaldeathendpoint."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 25,
      "pmid": "40468355",
      "title": "GUIDE: a prospective cohort study for blood-based early detection of gastrointestinal cancers using targeted DNA methylation and fragmentomics sequencing.",
      "citation": "Huang A, Guo DZ, Su ZX et al. GUIDE: a prospective cohort study for blood-based early detection of gastrointestinal cancers using targeted DNA methylation and fragmentomics sequencing. Molecular cancer. 2025.",
      "doi": "10.1186/s12943-025-02367-x",
      "pmcid": "PMC12139136",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40468355/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40468355/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID40468355",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "GUIDEGutSeer originaltraining/validation andlocked846person independentGIcohort shows~81.5%sensitivity/94.4%specificity andprecancer detection.",
      "what_it_does_not_show": "Mixedin/outpatient knownGIcases andnew assay, notGalleri ormortalityscreening trial; stage detection not benefit proof.",
      "confounders_present": [
        "Mixedin/outpatient knownGIcases andnew assay, notGalleri ormortalityscreening trial; stage detection not benefit proof."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 26,
      "pmid": "39948555",
      "title": "Prospective validation study: a non-invasive circulating tumor DNA-based assay for simultaneous early detection of multiple cancers in asymptomatic adults.",
      "citation": "Nguyen LHD, Nguyen THH, Le VH et al. Prospective validation study: a non-invasive circulating tumor DNA-based assay for simultaneous early detection of multiple cancers in asymptomatic adults. BMC medicine. 2025.",
      "doi": "10.1186/s12916-025-03929-y",
      "pmcid": "PMC11827191",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39948555/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39948555/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "K_DETEK_NCT05227261",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC2"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "KDETEK9057asymptomatic≥40Vietnam;9024eligible,43signals,17malignancies,PPV39.5%, one-yearnegative follow-up; TOO52.9%.",
      "what_it_does_not_show": "Smallcancercount and12monthascertainment constrain estimates; alternativeSPOTMASandage40scope differ. Originalcallsutility butdoesnot measuremortality utility.",
      "confounders_present": [
        "Smallcancercount and12monthascertainment constrain estimates; alternativeSPOTMASandage40scope differ. Originalcallsutility butdoesnot measuremortality utility."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 27,
      "pmid": "40833414",
      "title": "Fragmentation signatures in cancer patients resemble those of patients with vascular or autoimmune diseases.",
      "citation": "Curtis SD, Liu T, Bai Y et al. Fragmentation signatures in cancer patients resemble those of patients with vascular or autoimmune diseases. Proceedings of the National Academy of Sciences of the United States of America. 2025.",
      "doi": "10.1073/pnas.2426890122",
      "pmcid": "PMC12402995",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40833414/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40833414/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "ErratumIn: PMID41628341"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID40833414",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "Originalfragmentomics study showsvenousthromboembolism/autoimmune profiles resemblecancer andproducefalsepositives underbinaryclassifiers; addingproteins/multiclassapproach improves discrimination.",
      "what_it_does_not_show": "Specificity challenge to this assay class, not direct evidence against Galleri methylation specificity. Original correction41628341 adds funding acknowledgments rather than numerical results. No mortality endpoint was measured.",
      "confounders_present": [
        "Specificity challenge to this assay class, not direct evidence against Galleri methylation specificity. Original correction41628341 adds funding acknowledgments rather than numerical results. No mortality endpoint was measured."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 28,
      "pmid": "41153790",
      "title": "A Protein-Based Blood Test for Multi-Cancer Diagnostics.",
      "citation": "Held D, Bolland S, Freese R et al. A Protein-Based Blood Test for Multi-Cancer Diagnostics. Biomedicines. 2025.",
      "doi": "10.3390/biomedicines13102510",
      "pmcid": "PMC12561768",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41153790/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41153790/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "ErratumIn: PMID41595793"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID41153790",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "Alternative16proteinclassifier141knowncancercases/119healthy controls reports100%sensitivity and97%specificity.",
      "what_it_does_not_show": "Small case-control model development cannot establish prospective screening100% sensitivity or survival benefit. Original correction41595793 changes male breast percentage to3.3% and specificity95%CI to90–99% for breast and92–99% for lung; authors state conclusions unchanged. This is not Galleri.",
      "confounders_present": [
        "Small case-control model development cannot establish prospective screening100% sensitivity or survival benefit. Original correction41595793 changes male breast percentage to3.3% and specificity95%CI to90–99% for breast and92–99% for lung; authors state conclusions unchanged. This is not Galleri."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 29,
      "pmid": "35603292",
      "title": "Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test.",
      "citation": "Hinestrosa JP, Kurzrock R, Lewis JM et al. Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test. Communications medicine. 2022.",
      "doi": "10.1038/s43856-022-00088-6",
      "pmcid": "PMC9053211",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35603292/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35603292/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID35603292",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "EVproteinpilot139pathologyconfirmed stageI/IIcases versus184controls; sensitivity71.2% at99.5%specificity withlarge cancersitedifferences.",
      "what_it_does_not_show": "Selectedcase-control pilot, different3cancerassay; earlystage discrimination is notclinicalscreeningbenefit orallcancerperformance.",
      "confounders_present": [
        "Selectedcase-control pilot, different3cancerassay; earlystage discrimination is notclinicalscreeningbenefit orallcancerperformance."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 30,
      "pmid": "41411611",
      "title": "Multicancer Early Detection Blood Test Performance in Cancer Survivors From the PATHFINDER Study.",
      "citation": "Marinac CR, O'Donnell EK, Clarke CA et al. Multicancer Early Detection Blood Test Performance in Cancer Survivors From the PATHFINDER Study. JCO precision oncology. 2025.",
      "doi": "10.1200/PO-25-00498",
      "pmcid": "PMC12721668",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41411611/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41411611/",
      "tier": "A",
      "source_tier": "A",
      "kind": "secondary_trial_diagnostic_report",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PATHFINDER_NCT04241796",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC2"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "PATHFINDER1609survivor subgroup,20signals and10newdiagnoses includingsecondprimaries/recurrences;testmetrics describedsimilar.",
      "what_it_does_not_show": "Sameparentcohort; survivorsdiffer fromaverage-riskfirstscreening andno randomsurvival comparison. Added subgroups do notcreateefficacyreplication.",
      "confounders_present": [
        "Sameparentcohort; survivorsdiffer fromaverage-riskfirstscreening andno randomsurvival comparison. Added subgroups do notcreateefficacyreplication."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": [
        "Survivor subgroup of PATHFINDER."
      ]
    },
    {
      "n": 31,
      "pmid": "39818231",
      "title": "Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study.",
      "citation": "Nadauld L, McDonnell CH, Dilaveri CA et al. Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study. The Lancet. Oncology. 2025.",
      "doi": "10.1016/S1470-2045(24)00645-4",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39818231/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39818231/",
      "tier": "A",
      "source_tier": "A",
      "kind": "secondary_patient_reported_outcomes",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PATHFINDER_NCT04241796",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "PATHFINDERPROsecondary study foundtransienthigheranxiety aftersignals,meanreturn towardbaseline by12months andhighsatisfaction; response counts differ bygroup/time.",
      "what_it_does_not_show": "Sameparenttrial andmissing questionnaires; averages/satisfaction cannotexcludeindividualdistress orprove netmortalitybenefit. No randomscreeningpsychosocialcontrol.",
      "confounders_present": [
        "Sameparenttrial andmissing questionnaires; averages/satisfaction cannotexcludeindividualdistress orprove netmortalitybenefit. No randomscreeningpsychosocialcontrol."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": [
        "Patient-reported outcome follow-up of PATHFINDER."
      ]
    },
    {
      "n": 32,
      "pmid": "40926064",
      "title": "The impact of cancer expectations on psychological responses following a cancer signal detected result in asymptomatic multi-cancer detection (MCED) testing.",
      "citation": "Marlow LAV, Schmeising-Barnes N, Waller J. The impact of cancer expectations on psychological responses following a cancer signal detected result in asymptomatic multi-cancer detection (MCED) testing. British journal of cancer. 2025.",
      "doi": "10.1038/s41416-025-03180-5",
      "pmcid": "PMC12603331",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40926064/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40926064/",
      "tier": "A",
      "source_tier": "A",
      "kind": "original_qualitative_trial_substudy",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "NHS_Galleri_NCT05611632",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "41selectedNHSsignal-positive interviewees describeexpectations,uncertainty andreassurance differences with/withoutcancer.",
      "what_it_does_not_show": "Purposivequalitative subset notincidenceofharm orcausal mortalityevidence; sameNHSparent, self-reportedcancerstatus.",
      "confounders_present": [
        "Purposivequalitative subset notincidenceofharm orcausal mortalityevidence; sameNHSparent, self-reportedcancerstatus."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 33,
      "pmid": "38520825",
      "title": "Attitudes to multi-cancer early detection (MCED) blood tests for population-based screening: A qualitative study in Great Britain.",
      "citation": "Schmeising-Barnes N, Waller J, Marlow LAV. Attitudes to multi-cancer early detection (MCED) blood tests for population-based screening: A qualitative study in Great Britain. Social science & medicine (1982). 2024.",
      "doi": "10.1016/j.socscimed.2024.116762",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38520825/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38520825/",
      "tier": "A",
      "source_tier": "A",
      "kind": "original_qualitative_focus_groups",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID38520825",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Weak",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "53Britishadults50–77 focusgroups expressenthusiasm foreasybloodscreening andconcernaboutfalsepositives/followupprocedures.",
      "what_it_does_not_show": "Beliefsaboutreduceddeaths areparticipants'views ratherthanevidence; hypotheticalacceptability notactualscreeningbenefit/harmrate.",
      "confounders_present": [
        "Beliefsaboutreduceddeaths areparticipants'views ratherthanevidence; hypotheticalacceptability notactualscreeningbenefit/harmrate."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 34,
      "pmid": "39774314",
      "title": "Prenatal cfDNA Sequencing and Incidental Detection of Maternal Cancer.",
      "citation": "Turriff AE, Annunziata CM, Malayeri AA et al. Prenatal cfDNA Sequencing and Incidental Detection of Maternal Cancer. The New England journal of medicine. 2024.",
      "doi": "10.1056/NEJMoa2401029",
      "pmcid": "PMC11711700",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39774314/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39774314/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID39774314",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "IDENTIFY selected107pregnant/postpartumunusualprenatalcfDNAresults;52occultcancers, WBMRIsensitivity98% andspecificity88.5%; certaincopy-numberpatternstronglypredictive.",
      "what_it_does_not_show": "Extremelyenrichedabnormaltestreferredpopulation andpregnancy context; notgeneralpopulationMRI/Galleri screeningperformance or mortalityreduction.",
      "confounders_present": [
        "Extremelyenrichedabnormaltestreferredpopulation andpregnancy context; notgeneralpopulationMRI/Galleri screeningperformance or mortalityreduction."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 35,
      "pmid": "29348365",
      "title": "Detection and localization of surgically resectable cancers with a multi-analyte blood test.",
      "citation": "Cohen JD, Li L, Wang Y et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science (New York, N.Y.). 2018.",
      "doi": "10.1126/science.aar3247",
      "pmcid": "PMC6080308",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29348365/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29348365/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID29348365",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "CancerSEEK1005clinicallydetectednonmetastatic cancers/812healthy controls showedmedian70%detection and>99%specificity.",
      "what_it_does_not_show": "Differentmutation/proteinassay andknowncasecontrol design; no asymptomaticprospective ormortalitycomparison. Detectionlocalization notcure.",
      "confounders_present": [
        "Differentmutation/proteinassay andknowncasecontrol design; no asymptomaticprospective ormortalitycomparison. Detectionlocalization notcure."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 36,
      "pmid": "32694610",
      "title": "Non-invasive early detection of cancer four years before conventional diagnosis using a blood test.",
      "citation": "Chen X, Gole J, Gore A et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nature communications. 2020.",
      "doi": "10.1038/s41467-020-17316-z",
      "pmcid": "PMC7374162",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32694610/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32694610/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID32694610",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC3"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "PanSeerstoredTZLplasma605asymptomatic subjects including191subsequentcancers showedprediagnostic signals up to4years;223postdiagnosiscases alsoassayed.",
      "what_it_does_not_show": "Nestedselectedstoredsamples do notestablish liveclinicalscreening intervention or mortalitybenefit; prospectiveconfirmation required, notGalleri.",
      "confounders_present": [
        "Nestedselectedstoredsamples do notestablish liveclinicalscreening intervention or mortalitybenefit; prospectiveconfirmation required, notGalleri."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 37,
      "pmid": "27501770",
      "title": "Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.",
      "citation": "Villani A, Shore A, Wasserman JD et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. The Lancet. Oncology. 2016.",
      "doi": "10.1016/S1470-2045(16)30249-2",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27501770/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27501770/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "TP53_comprehensive_surveillance_89",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "89TP53carrierschosecomprehensivesurveillance ornot;19crossedover;59under surveillance,5yearpostdiagnosissurvival88.8%vs59.6%,falsepositives/negativesoccurred.",
      "what_it_does_not_show": "As-treatedselfselection,leadtime andmulti-modalitybundle inhighrisk hereditary families; notisolatedMRIcausalbenefit or generalaverage-riskcommercialscreening.",
      "confounders_present": [
        "As-treatedselfselection,leadtime andmulti-modalitybundle inhighrisk hereditary families; notisolatedMRIcausalbenefit or generalaverage-riskcommercialscreening."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 38,
      "pmid": "35053544",
      "title": "Whole-Body MRI Surveillance-Baseline Findings in the Swedish Multicentre Hereditary TP53-Related Cancer Syndrome Study (SWEP53).",
      "citation": "Omran M, Tham E, Brandberg Y et al. Whole-Body MRI Surveillance-Baseline Findings in the Swedish Multicentre Hereditary TP53-Related Cancer Syndrome Study (SWEP53). Cancers. 2022.",
      "doi": "10.3390/cancers14020380",
      "pmcid": "PMC8773910",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35053544/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35053544/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "SWEP53_TP53_baseline",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "SWEP53baseline61adultTP53carriers;19furtherworkups,3asymptomatic malignancies;dedicatedbrain/breastimagingincluded.",
      "what_it_does_not_show": "Highriskhereditarysurveillance andsinglebaseline yield; no assignedmortalitycontrast orall-comercommercialMRIequivalence.",
      "confounders_present": [
        "Highriskhereditarysurveillance andsinglebaseline yield; no assignedmortalitycontrast orall-comercommercialMRIequivalence."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 39,
      "pmid": "26597793",
      "title": "Impact of whole-body MRI in a general population study.",
      "citation": "Schmidt CO, Sierocinski E, Hegenscheid K et al. Impact of whole-body MRI in a general population study. European journal of epidemiology. 2016.",
      "doi": "10.1007/s10654-015-0101-y",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/26597793/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26597793/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "SHIP_Trend_whole_body_MRI",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "null",
      "what_it_shows": "SHIPTrend4420participants/2188MRI;2.5year follow-upfoundnegligibleoverallQoL/depressiondifferences withMRIorincidentaldisclosures.",
      "what_it_does_not_show": "OptionalMRIparticipation andattritionweighting; overallpsychosocialnulldoesnot establish clinicalbenefit or ruleoutshort-term/individualdistress.",
      "confounders_present": [
        "OptionalMRIparticipation andattritionweighting; overallpsychosocialnulldoesnot establish clinicalbenefit or ruleoutshort-term/individualdistress."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 40,
      "pmid": "34996801",
      "title": "Effects of whole-body MRI on outpatient health service costs: a general-population prospective cohort study in Mecklenburg-Vorpommern, Germany.",
      "citation": "Schmidt CO, Sierocinski E, Baumeister S et al. Effects of whole-body MRI on outpatient health service costs: a general-population prospective cohort study in Mecklenburg-Vorpommern, Germany. BMJ open. 2022.",
      "doi": "10.1136/bmjopen-2021-056572",
      "pmcid": "PMC8744128",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34996801/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34996801/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "SHIP_and_SHIPTrend_MRI",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "SHIP5019withinsurance,2969MRI,propensityweightednonparticipants; incidentalfindings32%,outpatientcosts about€295/11.6%higher over2years.",
      "what_it_does_not_show": "Quasiexperimentalnotrandomized, MRIplusclinicalworkupandselectionmayconfound; costsarenotautomaticallymedicalharms andnocancermortalitybenefitcomparison.",
      "confounders_present": [
        "Quasiexperimentalnotrandomized, MRIplusclinicalworkupandselectionmayconfound; costsarenotautomaticallymedicalharms andnocancermortalitybenefitcomparison."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 41,
      "pmid": "40588398",
      "title": "Evaluation of whole-body MRI for cancer early detection in Li-Fraumeni syndrome.",
      "citation": "Sodde P, Hyder Z, Pugh S et al. Evaluation of whole-body MRI for cancer early detection in Li-Fraumeni syndrome. Journal of medical genetics. 2025.",
      "doi": "10.1136/jmg-2025-110704",
      "pmcid": "PMC12505049",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40588398/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40588398/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID40588398",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "Retrospective75LFSadultstotal325WBscans;9of17cancersMRI-detected,89scansbenignincidentalfindingsprompted53investigations;sensitivity42.9%.",
      "what_it_does_not_show": "HighlyselectedTP53surveillance ratherthangeneralpopulation,DTCorGalleri; repeatedscans/subjects notindependentcases andno controlledmortalityendpoint.",
      "confounders_present": [
        "HighlyselectedTP53surveillance ratherthangeneralpopulation,DTCorGalleri; repeatedscans/subjects notindependentcases andno controlledmortalityendpoint."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 42,
      "pmid": "18818038",
      "title": "Incidental findings in healthy control research subjects using whole-body MRI.",
      "citation": "Morin SH, Cobbold JF, Lim AK et al. Incidental findings in healthy control research subjects using whole-body MRI. European journal of radiology. 2009.",
      "doi": "10.1016/j.ejrad.2008.08.006",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/18818038/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/18818038/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID18818038",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "148healthyresearchvolunteers,29.1%abnormalWBscans,12.8%clinicallysignificantfindings; prevalencehigherwithage/BMI.",
      "what_it_does_not_show": "Researchcohortmedian36 andsinglehospital; clinicalsignificancelabelnot provennetbenefit or mortalityprevention. No comparisonintervention.",
      "confounders_present": [
        "Researchcohortmedian36 andsinglehospital; clinicalsignificancelabelnot provennetbenefit or mortalityprevention. No comparisonintervention."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 43,
      "pmid": "27635171",
      "title": "Whole-Body MRI Screening in Asymptomatic Subjects; Preliminary Experience and Long-Term Follow-Up Findings.",
      "citation": "Ulus S, Suleyman E, Ozcan UA et al. Whole-Body MRI Screening in Asymptomatic Subjects; Preliminary Experience and Long-Term Follow-Up Findings. Polish journal of radiology. 2016.",
      "doi": "10.12659/PJR.897570",
      "pmcid": "PMC5008738",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27635171/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27635171/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID27635171",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "118consecutiveasymptomatichealthcheckparticipants;103benignlesionsin83subjects,2malignantand1precancerouslesionfound.",
      "what_it_does_not_show": "Detectionyield andanatomiccoverage notmortality/netbenefit; selectedhealthcheckcohort andsmall malignancydenominator.",
      "confounders_present": [
        "Detectionyield andanatomiccoverage notmortality/netbenefit; selectedhealthcheckcohort andsmall malignancydenominator."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 44,
      "pmid": "22911290",
      "title": "Potentially relevant incidental findings on research whole-body MRI in the general adult population: frequencies and management.",
      "citation": "Hegenscheid K, Seipel R, Schmidt CO et al. Potentially relevant incidental findings on research whole-body MRI in the general adult population: frequencies and management. European radiology. 2013.",
      "doi": "10.1007/s00330-012-2636-6",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22911290/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/22911290/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "SHIP_whole_body_MRI",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "SHIP2500WBMRI;36.2%potentiallyrelevantincidentalfindings,31.5%disclosed,mostnatureunclear;9urgentreferrals.",
      "what_it_does_not_show": "Reader/advisoryclassification isnotfullyconfirmedmalignancy; extraorganimagingin subsets andsharedSHIPparticipants requiregrouping. No mortalitytrial.",
      "confounders_present": [
        "Reader/advisoryclassification isnotfullyconfirmedmalignancy; extraorganimagingin subsets andsharedSHIPparticipants requiregrouping. No mortalitytrial."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 45,
      "pmid": "32860149",
      "title": "The effects of incidental findings from whole-body MRI on the frequency of biopsies and detected malignancies or benign conditions in a general population cohort study.",
      "citation": "Richter A, Sierocinski E, Singer S et al. The effects of incidental findings from whole-body MRI on the frequency of biopsies and detected malignancies or benign conditions in a general population cohort study. European journal of epidemiology. 2020.",
      "doi": "10.1007/s10654-020-00679-4",
      "pmcid": "PMC7524843",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32860149/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32860149/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "SHIP_and_SHIPTrend_MRI",
      "access_depth": "full_text_partial",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph10, 1:Methods:paragraph23, 2:Results:paragraph1, 2:Results:paragraph7, 2:Results:paragraph14. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [
        "M3"
      ],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": true,
      "endogenous": false,
      "direction": "supports",
      "what_it_shows": "OriginalM/RSHIP6753participants withoptionalMRI3371; linkedbiopsyrate6.9pre to9.9post per100observationyears;largeabsoluteincrease innonmalignantresults, higherwithdisclosedMRI/labfindings.",
      "what_it_does_not_show": "Concurrentlabdisclosures,selection andregionalpathologycoverage constrainMRI-specificcausation; increasedbiopsiesdonot quantifyoverdiagnosisorproveallMRI net harm. No randomizedmortalitycontrast.",
      "confounders_present": [
        "Concurrentlabdisclosures,selection andregionalpathologycoverage constrainMRI-specificcausation; increasedbiopsiesdonot quantifyoverdiagnosisorproveallMRI net harm. No randomizedmortalitycontrast."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.",
      "shared_components": [
        "Optional MRI plus laboratory disclosures in overlapping SHIP/SHIPTrend cohorts; not randomized exposure."
      ]
    },
    {
      "n": 46,
      "pmid": "23239059",
      "title": "Psychosocial consequences and severity of disclosed incidental findings from whole-body MRI in a general population study.",
      "citation": "Schmidt CO, Hegenscheid K, Erdmann P et al. Psychosocial consequences and severity of disclosed incidental findings from whole-body MRI in a general population study. European radiology. 2013.",
      "doi": "10.1007/s00330-012-2723-8",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/23239059/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/23239059/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "SHIP_whole_body_MRI",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "405SHIPincidental-finding surveyrespondents;28.6%moderate/severedistressafterdisclosure despite96%satisfaction;subjective/radiologicalseverityagreementlow.",
      "what_it_does_not_show": "Selecteddisclosedrespondents,no randomcounterfactual andsameSHIPparent; acuteharm/satisfactionarenot universalorlongtermnetbenefitmetrics.",
      "confounders_present": [
        "Selecteddisclosedrespondents,no randomcounterfactual andsameSHIPparent; acuteharm/satisfactionarenot universalorlongtermnetbenefitmetrics."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 47,
      "pmid": "29565420",
      "title": "False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care.",
      "citation": "Tandy-Connor S, Guiltinan J, Krempely K et al. False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care. Genetics in medicine : official journal of the American College of Medical Genetics. 2018.",
      "doi": "10.1038/gim.2018.38",
      "pmcid": "PMC6301953",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29565420/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29565420/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID29565420",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC4"
      ],
      "favors_models": [
        "M3"
      ],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "49clinicalconfirmationreferralsfromDTCrawdata/thirdpartyinterpretation;40%reportedvariantsfalsepositive andsomeincreased-risklabelsclinicallybenign.",
      "what_it_does_not_show": "Referral-enrichedvariantdenominator; doesnot mean40%ofallDTCcustomersortestsarewrong. GeneticriskinterpretationnotMCEDdiagnosisandnotclinicalmortalitytrial.",
      "confounders_present": [
        "Referral-enrichedvariantdenominator; doesnot mean40%ofallDTCcustomersortestsarewrong. GeneticriskinterpretationnotMCEDdiagnosisandnotclinicalmortalitytrial."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 48,
      "pmid": "21714641",
      "title": "Reduced lung-cancer mortality with low-dose computed tomographic screening.",
      "citation": "National Lung Screening Trial Research Team, Aberle DR, Adams AM et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. The New England journal of medicine. 2011.",
      "doi": "10.1056/NEJMoa1102873",
      "pmcid": "PMC4356534",
      "url": "https://pubmed.ncbi.nlm.nih.gov/21714641/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/21714641/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "NLST_NCT00047385",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC2",
        "SC3"
      ],
      "favors_models": [
        "M4"
      ],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "supports",
      "what_it_shows": "NLST53454highrisksmokers randomized3annualLDCTvschestradiography; lungcancermortality20%relativeandallcause6.7%lower atinitialfollow-up,withmanypositive-screenfalsealarms.",
      "what_it_does_not_show": "Positive disease-specificscreeningmortalityproof indefinedrisk/context, notGalleri; higherincidenceandprocedureharms mustremain. Differentmodalitycannot supplyexactleadthreshold.",
      "confounders_present": [
        "Positive disease-specificscreeningmortalityproof indefinedrisk/context, notGalleri; higherincidenceandprocedureharms mustremain. Differentmodalitycannot supplyexactleadthreshold."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": true,
      "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.",
      "shared_components": []
    },
    {
      "n": 49,
      "pmid": "31995683",
      "title": "Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.",
      "citation": "de Koning HJ, van der Aalst CM, de Jong PA et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. The New England journal of medicine. 2020.",
      "doi": "10.1056/NEJMoa1911793",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31995683/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31995683/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "NELSON_NL580",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC2",
        "SC3"
      ],
      "favors_models": [
        "M4"
      ],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "supports",
      "what_it_shows": "NELSONrandomizedhighrisksmokers50–74 tovolumetricCT/noscreening;10yearmale lungdeathRR.76CI.61–.94, women.67CI.38–1.14.",
      "what_it_does_not_show": "Truepositiveclinicalscreeneffect indefinedpopulation; sexsubgroupimprecise, differenttest/site/carepathway. NoMCEDmortalitycrossing.",
      "confounders_present": [
        "Truepositiveclinicalscreeneffect indefinedpopulation; sexsubgroupimprecise, differenttest/site/carepathway. NoMCEDmortalitycrossing."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": true,
      "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.",
      "shared_components": []
    },
    {
      "n": 50,
      "pmid": "31260833",
      "title": "Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial.",
      "citation": "National Lung Screening Trial Research Team. Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019.",
      "doi": "10.1016/j.jtho.2019.05.044",
      "pmcid": "PMC6764895",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31260833/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31260833/",
      "tier": "A",
      "source_tier": "A",
      "kind": "randomized_trial_long_term_followup",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "NLST_NCT00047385",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC2",
        "SC3"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "mixed",
      "what_it_shows": "SameNLSTextendedmortalitymedian12.3years;lungdeathRR.92CI.85–1.00,dilutionadjusted.89;NNS303,allcauseintervalincludesnull.",
      "what_it_does_not_show": "Longerhorizonaltersestimates; repeatedparentfollow-upnotindependenttrialor evidenceforallcancer bloodscreens.",
      "confounders_present": [
        "Longerhorizonaltersestimates; repeatedparentfollow-upnotindependenttrialor evidenceforallcancer bloodscreens."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": [
        "Extended follow-up of the same NLST screening allocation."
      ]
    },
    {
      "n": 51,
      "pmid": "33991479",
      "title": "Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.",
      "citation": "Menon U, Gentry-Maharaj A, Burnell M et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet (London, England). 2021.",
      "doi": "10.1016/S0140-6736(21)00731-5",
      "pmcid": "PMC8192829",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33991479/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33991479/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "UKCTOCS_NCT00058032",
      "access_depth": "full_text_partial",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph4, 1:Methods:paragraph8, 1:Methods:paragraph11, 2:Results:paragraph3, 2:Results:paragraph11, 2:Results:paragraph16. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC2",
        "SC3"
      ],
      "favors_models": [
        "M2",
        "M4"
      ],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": true,
      "endogenous": true,
      "direction": "mixed",
      "what_it_shows": "Original M/R UKCTOCS 202562 average-risk women 50–74, median 16.3 years; MMS increased stage I 47.2% and reduced stage IV 24.5%, but ovarian/tubal deaths not lower P=.58; USS P=.36.",
      "what_it_does_not_show": "Direct stage/mortality dissociation blocks universal surrogate claim; does not prove Galleri mortality null because assay/site differ. Positive clinical mortality crossing absent for ovarian programme. The combined stage III/IV reduction (10.2%, 95% CI −21.3 to 2.4) was not significant, so the dissociation is stage IV-only.",
      "confounders_present": [
        "Direct stage/mortality dissociation blocks universal surrogate claim; does not prove Galleri mortality null because assay/site differ. Positive clinical mortality crossing absent for ovarian programme. The combined stage III/IV reduction (10.2%, 95% CI −21.3 to 2.4) was not significant, so the dissociation is stage IV-only."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": true,
      "decisive_test_note": "Pivotal test, including null or negative results and restricted contexts; this flag is not a positive threshold crossing.",
      "shared_components": []
    },
    {
      "n": 52,
      "pmid": "37183782",
      "title": "Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.",
      "citation": "Menon U, Gentry-Maharaj A, Burnell M et al. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial. Health technology assessment (Winchester, England). 2025.",
      "doi": "10.3310/BHBR5832",
      "pmcid": "PMC10542866",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37183782/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37183782/",
      "tier": "A",
      "source_tier": "A",
      "kind": "original_comprehensive_trial_report",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "UKCTOCS_NCT00058032",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC2",
        "SC3",
        "SC4"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "mixed",
      "what_it_shows": "UKCTOCSoriginalcomprehensivefollow-upretainsmortalitynull andstagechanges; unnecessaryfalsepositive surgery2.3perMMSscreen-detectedcase and10perUSSdetectedcase.",
      "what_it_does_not_show": "Sameparenttrialanddenominatorsnotper-personrisk; no independentRCT ordirectGalleri harmsrates. Thisisoriginaltrialreport,notprotocol.",
      "confounders_present": [
        "Sameparenttrialanddenominatorsnotper-personrisk; no independentRCT ordirectGalleri harmsrates. Thisisoriginaltrialreport,notprotocol."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": [
        "Comprehensive original UKCTOCS trial report, not a new screening allocation."
      ]
    },
    {
      "n": 53,
      "pmid": "38581198",
      "title": "Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.",
      "citation": "Martin RM, Turner EL, Young GJ et al. Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial. JAMA. 2024.",
      "doi": "10.1001/jama.2024.4011",
      "pmcid": "PMC10999004",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38581198/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38581198/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "CAP_ISRCTN92187251",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC2",
        "SC3"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "mixed",
      "what_it_shows": "CAP415357men50–69clusterinvitationPSA;15yearsecondary prostate-deathRR.92CI.85–.99,absoluterisk.69%vs.78%;lowgrade/localizeddetectionincreased,allcauseeffectnonsignificant.",
      "what_it_does_not_show": "Original10yearprimarynulland15yearsecondaryresultbothmatter; differentorgan,testsandinvitationnotGalleri. Absoluteeffectsmallanddiagnostic/treatmentdeathsreported.",
      "confounders_present": [
        "Original10yearprimarynulland15yearsecondaryresultbothmatter; differentorgan,testsandinvitationnotGalleri. Absoluteeffectsmallanddiagnostic/treatmentdeathsreported."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 54,
      "pmid": "36214590",
      "title": "Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death.",
      "citation": "Bretthauer M, Løberg M, Wieszczy P et al. Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death. The New England journal of medicine. 2022.",
      "doi": "10.1056/NEJMoa2208375",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36214590/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36214590/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "NordICC_NCT00883792",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC2",
        "SC3"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "mixed",
      "what_it_shows": "NordICC84585adults55–64 randomizedinvitationcolonoscopy/usualcare;42%uptake;10yearincidenceRR.82positive,deathRR.90CI.64–1.16null;15majorbleeds.",
      "what_it_does_not_show": "Invitationsharedcareeffect differsfromprocedureefficacy amongcompliers; incidencebenefitdoesnotbyitselfestablishmortalitybenefit. NoGalleriinference.",
      "confounders_present": [
        "Invitationsharedcareeffect differsfromprocedureefficacy amongcompliers; incidencebenefitdoesnotbyitselfestablishmortalitybenefit. NoGalleriinference."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 55,
      "pmid": "42102826",
      "title": "Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial.",
      "citation": "Kaminski MF, Kalager M, Løberg M et al. Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial. Lancet (London, England). 2026.",
      "doi": "10.1016/S0140-6736(26)00508-8",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42102826/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42102826/",
      "tier": "A",
      "source_tier": "A",
      "kind": "randomized_trial_long_term_followup",
      "status_flags": [
        "ErratumIn: PMID42119586"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "NordICC_NCT00883792",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC2",
        "SC3"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "mixed",
      "what_it_shows": "SameNordICC13yearfollow-up incidencebenefit andcancerdeathRR.88CI.68–1.08;lowercontrolmortalitythanexpectedmayreducepower.",
      "what_it_does_not_show": "No significantmortalitycontrast,perprotocolnonrandomadherencesensitive;Erratum42119586attached. AvoiduncorrectedfinegrainsubgroupCIwhichabstractformatsanegativeupperbound.",
      "confounders_present": [
        "No significantmortalitycontrast,perprotocolnonrandomadherencesensitive;Erratum42119586attached. AvoiduncorrectedfinegrainsubgroupCIwhichabstractformatsanegativeupperbound."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": [
        "Thirteen-year follow-up of the same NordICC trial."
      ]
    },
    {
      "n": 56,
      "pmid": "41160819",
      "title": "European Study of Prostate Cancer Screening - 23-Year Follow-up.",
      "citation": "Roobol MJ, de Vos II, Månsson M et al. European Study of Prostate Cancer Screening - 23-Year Follow-up. The New England journal of medicine. 2025.",
      "doi": "10.1056/NEJMoa2503223",
      "pmcid": "",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41160819/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41160819/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "ErratumIn: PMID41812212"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "ERSPC_ISRCTN49127736",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC2",
        "SC3"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "supports",
      "what_it_shows": "ERSPC23yearfollow-up core162236men55–69randomizedPSAinvitation; prostate-deathRR.87CI.80–.95,absolutereduction.22%,incidencehigher1.30.",
      "what_it_does_not_show": "Truepositiveparticularscreeningcontext butoverdiagnosisremains,notGallerioreverycancer. AttachedErratum41812212needsdetailcheck; notdirectMCEDmortalityevidence.",
      "confounders_present": [
        "Truepositiveparticularscreeningcontext butoverdiagnosisremains,notGallerioreverycancer. AttachedErratum41812212needsdetailcheck; notdirectMCEDmortalityevidence."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 57,
      "pmid": "32800099",
      "title": "Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial.",
      "citation": "Duffy SW, Vulkan D, Cuckle H et al. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. The Lancet. Oncology. 2020.",
      "doi": "10.1016/S1470-2045(20)30398-3",
      "pmcid": "PMC7491203",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32800099/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32800099/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID32800099",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC2",
        "SC3"
      ],
      "favors_models": [],
      "evidence_class": "Strong",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "mixed",
      "what_it_shows": "UKAge160921women randomizedmammography39–41through48orusualage50screen;10yearbreastdeathRR.75positive,laterintervalRR.98null.",
      "what_it_does_not_show": "BelowregisteredGalleriageatbaseline anddifferentassay; timinganddisease-specificboundarycontext only,notexactleadclinicalcrossingorproofallstagechangesbenefit.",
      "confounders_present": [
        "BelowregisteredGalleriageatbaseline anddifferentassay; timinganddisease-specificboundarycontext only,notexactleadclinicalcrossingorproofallstagechangesbenefit."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 58,
      "pmid": "27224642",
      "title": "The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer.",
      "citation": "Field JK, Duffy SW, Baldwin DR et al. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health technology assessment (Winchester, England). 2016.",
      "doi": "10.3310/hta20400",
      "pmcid": "PMC4904185",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27224642/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27224642/",
      "tier": "A",
      "source_tier": "A",
      "kind": "rct",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "UKLS_ISRCTN78513845",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC2",
        "SC3"
      ],
      "favors_models": [],
      "evidence_class": "Moderate",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": true,
      "direction": "supports",
      "what_it_shows": "UKLSpilot4055highriskadults50–75randomizedCT/usualcare;42detectedcancers,85.7%stage1/2;temporarydistressandcostmodelreported.",
      "what_it_does_not_show": "Pilotfeasibilitywithsurrogate/costmodel,notactualmortalitycomparisonatthisreport; don'tborrowNLSTdeathbenefitorthisstageyieldforGalleri.",
      "confounders_present": [
        "Pilotfeasibilitywithsurrogate/costmodel,notactualmortalitycomparisonatthisreport; don'tborrowNLSTdeathbenefitorthisstageyieldforGalleri."
      ],
      "verification": "verified",
      "verification_note": "Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "",
      "shared_components": []
    },
    {
      "n": 59,
      "pmid": "42773207",
      "title": "Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study.",
      "citation": "Nabavizadeh N, McDonnell C, Kurbegov D et al. Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study. Nature medicine. 2026.",
      "doi": "10.1038/s41591-026-04618-w",
      "pmcid": "PMC13668646",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42773207/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/42773207/",
      "tier": "A",
      "source_tier": "A",
      "kind": "primary",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-11-02",
      "status_checked_on": "2026-11-02",
      "study_id": "PATHFINDER2_NCT05155605",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original abstract and PubMed metadata examined 2026-11-02 during the adversarial correction; no complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC1",
        "SC4"
      ],
      "favors_models": [
        "M3"
      ],
      "evidence_class": "Moderate",
      "system": "human observational",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "PATHFINDER 2 prospective single-arm study, 35,878 enrolled adults ≥50 without clinical suspicion of cancer; among 32,007 performance-analyzable participants, detection rate 0.54%, PPV 60.3%, episode sensitivity 39.3% (69.8% for 12 prespecified cancers), specificity 99.64%; 213 of 35,335 safety-analyzable participants (0.6%) had invasive procedures after a positive test.",
      "what_it_does_not_show": "Descriptive endpoints without hypothesis testing and no comparator arm; no mortality endpoint. The authors state that randomized trials and longer follow-up are needed to assess clinical utility. Strengthens the SC1 and harms record; does not address SC2.",
      "confounders_present": [
        "Descriptive endpoints without hypothesis testing and no comparator arm; no mortality endpoint. The authors state that randomized trials and longer follow-up are needed to assess clinical utility. Strengthens the SC1 and harms record; does not address SC2."
      ],
      "verification": "verified",
      "verification_note": "Added 2026-11-02 after adversarial review; PubMed record verified this session. Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "Not a decisive perturbation; descriptive or synthesis evidence added in correction.",
      "shared_components": []
    },
    {
      "n": 60,
      "pmid": "38583868",
      "title": "Cancer Stage Compared With Mortality as End Points in Randomized Clinical Trials of Cancer Screening: A Systematic Review and Meta-Analysis.",
      "citation": "Feng X, Zahed H, Onwuka J et al. Cancer Stage Compared With Mortality as End Points in Randomized Clinical Trials of Cancer Screening: A Systematic Review and Meta-Analysis. JAMA. 2024.",
      "doi": "10.1001/jama.2024.5814",
      "pmcid": "PMC11000135",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38583868/",
      "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38583868/",
      "tier": "B",
      "source_tier": "B",
      "kind": "systematic_review_meta_analysis",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-11-02",
      "status_checked_on": "2026-11-02",
      "study_id": "PMID38583868",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original abstract and PubMed metadata examined 2026-11-02 during the adversarial correction; no complete-paper or supplement audit claimed.",
      "relates_to_subclaims": [
        "SC3"
      ],
      "favors_models": [
        "M4"
      ],
      "evidence_class": "Moderate",
      "system": "human interventional",
      "decisive_perturbation": false,
      "endogenous": false,
      "direction": "mixed",
      "what_it_shows": "Systematic review and meta-analysis of 41 cancer-screening RCTs comparing stage III–IV incidence with cancer-specific mortality as end points; correlation between the two reductions varied by cancer type, high for ovarian and lung and weak for colorectal and prostate.",
      "what_it_does_not_show": "Tier B synthesis: frames SC3 but does not carry an experimental number; does not include a Galleri or MCED mortality result and does not validate a multi-cancer stage surrogate.",
      "confounders_present": [
        "Tier B synthesis: frames SC3 but does not carry an experimental number; does not include a Galleri or MCED mortality result and does not validate a multi-cancer stage surrogate."
      ],
      "verification": "verified",
      "verification_note": "Added 2026-11-02 after adversarial review; PubMed record verified this session. Bounded source attribution; not proof of the nominal mechanism.",
      "citation_context": {
        "retrieved": false,
        "supporting_count": 0,
        "mentioning_count": 0,
        "contrasting_count": 0,
        "notable_contrasting_statements": []
      },
      "discriminating_contrast": false,
      "decisive_test_note": "Not a decisive perturbation; descriptive or synthesis evidence added in correction.",
      "shared_components": []
    }
  ],
  "verification_summary": {
    "load_bearing_claims_checked": 65,
    "verified": 65,
    "unverified": 0,
    "contradicted": 0,
    "note": "Verified attribution is distinct from mechanism truth or complete body access."
  },
  "factual_issues_found": [],
  "cap_rules_applied": [
    {
      "subclaim_id": "SC1",
      "cap": "Γ",
      "cap_source": "universal",
      "triggered": true,
      "trigger_text_quoted": "Biomarker change without functional/phenotypic change caps at Γ.",
      "specific_trigger": "Prospective Galleri studies and the NHS intervention-arm performance report demonstrate genuine cancer detections with quantified false positives, missed cancers and tissue-origin guidance. Diagnostic accuracy is reported descriptively, not as a causal grade on whether detection exists. The helper-compatible Γ entry records the unbridged inference from that diagnostic signal to meaningful clinical benefit, not doubt that the test detects some cancers. Case-control sensitivity differs from screening performance and cannot be substituted into population benefit estimates.",
      "resulting_ceiling": "Γ"
    },
    {
      "subclaim_id": "SC3",
      "cap": "Γ",
      "cap_source": "universal",
      "triggered": true,
      "trigger_text_quoted": "Biomarker change without functional/phenotypic change caps at Γ.",
      "specific_trigger": "A stage shift is insufficient by itself to establish saved lives. UKCTOCS directly demonstrates more stageI and fewer stageIV ovarian/tubal diagnoses without a cancer-mortality reduction after16.3years. NHS-Galleri's stageIV secondary signal is retained, but the combined stageIII/IV primary endpoint was not met. Site-specific biology, lead time, overdiagnosis, treatment and competing mortality require direct validation; stage-to-mortality causal inference retains Γ.",
      "resulting_ceiling": "Γ"
    },
    {
      "subclaim_id": "SC4",
      "cap": "Α",
      "cap_source": "rubric",
      "triggered": true,
      "trigger_text_quoted": "For highly promoted but weakly causal narratives sustained by marker association or conceptual appeal.",
      "specific_trigger": "General-population full-body MRI and DTC testing lack a verified comparable net mortality benefit in the examined sources. MRI detects real lesions and some cancers, while incidental findings, investigations, costs and distress also occur. Hereditary TP53 surveillance and abnormal prenatal cfDNA workup are enriched contexts and different packages. A selected DTC confirmation series identifies false variants without implying40% of all consumer tests are wrong. Blanket clinical-benefit equivalence remains Α.",
      "resulting_ceiling": "Α"
    }
  ],
  "cap_precedence_resolutions": [
    {
      "collision": "Perturbation in a defined setting versus broader inference",
      "subclaim_scope_cap_binds_on": "Adding Galleri multi-cancer blood screening to usual care reduces cancer mortality in asymptomatic adults aged 50 and older.",
      "subclaim_scope_threshold_binds_on": "The precise experimentally tested subclaim scope",
      "resolution": "The exact-assay mortality claim has no positive crossing, so stage, blood-signal or treatment-intent data remain partial support under the disclosed clinical adaptation. Diagnostic accuracy is not itself causally graded. The primary stage null and secondary stageIV signal are different endpoint results and neither is recast as a cancer-death analysis. Clinical mortality trials of other modalities score within their own populations and do not transfer a positive result to Galleri. Independently complementary same-scope causal evidence would be assessed as a set; it is not present for this lead.",
      "note": "Convergent lines are assessed as a set; one weak leg is not re-capped over the assembled case."
    }
  ],
  "boundary_check_BGD": [
    {
      "subclaim_id": "SC1",
      "field_valid_perturbation_quote": "\n- Endogenous genetic manipulation in autochthonous models\n- Patient-derived system perturbation with matched rescue AND in vivo confirmation\n- Clonal tracking demonstrating persistence of dependency through selection pressure",
      "qualifying_evidence_present": "no",
      "qualifying_evidence_citation": "",
      "gamma_hard_rules_triggered": [
        "Diagnostic signal-to-clinical-benefit inference lacks a mortality/functional bridge; performance itself is descriptive"
      ],
      "disease_phenotype_relevance": "yes",
      "perturbation_result_positive": "no",
      "perturbation_result_note": "Prospective Galleri studies and the NHS intervention-arm performance report demonstrate genuine cancer detections with quantified false positives, missed cancers and tissue-origin guidance. Diagnostic accuracy is reported descriptively, not as a causal grade on whether detection exists. The helper-compatible Γ entry records the unbridged inference from that diagnostic signal to meaningful clinical benefit, not doubt that the test detects some cancers. Case-control sensitivity differs from screening performance and cannot be substituted into population benefit estimates.",
      "ceiling_from_boundary_check": "Γ"
    },
    {
      "subclaim_id": "SC2",
      "field_valid_perturbation_quote": "\n- Endogenous genetic manipulation in autochthonous models\n- Patient-derived system perturbation with matched rescue AND in vivo confirmation\n- Clonal tracking demonstrating persistence of dependency through selection pressure",
      "qualifying_evidence_present": "no",
      "qualifying_evidence_citation": "",
      "gamma_hard_rules_triggered": [
        "No verified positive randomized Galleri cancer-mortality result at the cutoff"
      ],
      "disease_phenotype_relevance": "yes",
      "perturbation_result_positive": "no",
      "perturbation_result_note": "No examined primary report provides a positive randomized Galleri cancer-mortality contrast. The2026 NHS trial randomized142250 adults aged50–77; its primary stageIII/IV endpoint was null, while the stageIV secondary contrast was favorable. These are stage endpoints, not deaths. Official trial information states that mortality follow-up continues. Detection, feasibility, reported treatment and favorable stage subsets cannot cross the registered mortality threshold. Γ reflects plausible partial clinical system support with an unverified mortality bridge, not proof that a mortality trial has refuted Galleri.",
      "ceiling_from_boundary_check": "Γ"
    },
    {
      "subclaim_id": "SC3",
      "field_valid_perturbation_quote": "\n- Endogenous genetic manipulation in autochthonous models\n- Patient-derived system perturbation with matched rescue AND in vivo confirmation\n- Clonal tracking demonstrating persistence of dependency through selection pressure",
      "qualifying_evidence_present": "no",
      "qualifying_evidence_citation": "",
      "gamma_hard_rules_triggered": [
        "Stage surrogate does not establish clinical mortality benefit"
      ],
      "disease_phenotype_relevance": "yes",
      "perturbation_result_positive": "no",
      "perturbation_result_note": "A stage shift is insufficient by itself to establish saved lives. UKCTOCS directly demonstrates more stageI and fewer stageIV ovarian/tubal diagnoses without a cancer-mortality reduction after16.3years. NHS-Galleri's stageIV secondary signal is retained, but the combined stageIII/IV primary endpoint was not met. Site-specific biology, lead time, overdiagnosis, treatment and competing mortality require direct validation; stage-to-mortality causal inference retains Γ.",
      "ceiling_from_boundary_check": "Γ"
    },
    {
      "subclaim_id": "SC4",
      "field_valid_perturbation_quote": "\n- Endogenous genetic manipulation in autochthonous models\n- Patient-derived system perturbation with matched rescue AND in vivo confirmation\n- Clonal tracking demonstrating persistence of dependency through selection pressure",
      "qualifying_evidence_present": "no",
      "qualifying_evidence_citation": "",
      "gamma_hard_rules_triggered": [
        "No exact comparable population-specific net clinical screening benefit"
      ],
      "disease_phenotype_relevance": "yes",
      "perturbation_result_positive": "no",
      "perturbation_result_note": "General-population full-body MRI and DTC testing lack a verified comparable net mortality benefit in the examined sources. MRI detects real lesions and some cancers, while incidental findings, investigations, costs and distress also occur. Hereditary TP53 surveillance and abnormal prenatal cfDNA workup are enriched contexts and different packages. A selected DTC confirmation series identifies false variants without implying40% of all consumer tests are wrong. Blanket clinical-benefit equivalence remains Α.",
      "ceiling_from_boundary_check": "Γ"
    }
  ],
  "thresholds_tested": [
    {
      "subclaim_id": "SC1",
      "threshold": "Δ",
      "requirement_quoted": "Requires at least one meaningful causal perturbation showing the proposed mechanism contributes to initiation, maintenance, or relapse.",
      "satisfied": "no",
      "supporting_evidence": [],
      "what_would_cross_it": "Keep diagnostic performance descriptive; verify interval-cancer ascertainment and modern assay performance prospectively, then separately demonstrate meaningful clinical benefit rather than applying a causal letter to accuracy."
    },
    {
      "subclaim_id": "SC2",
      "threshold": "Δ",
      "requirement_quoted": "Requires at least one meaningful causal perturbation showing the proposed mechanism contributes to initiation, maintenance, or relapse.",
      "satisfied": "no",
      "supporting_evidence": [],
      "what_would_cross_it": "A prespecified, adequately powered randomized Galleri-plus-usual-care comparison must demonstrate lower cancer mortality with blinded outcome adjudication, sufficient follow-up and intact standard screening."
    },
    {
      "subclaim_id": "SC3",
      "threshold": "Δ",
      "requirement_quoted": "Requires at least one meaningful causal perturbation showing the proposed mechanism contributes to initiation, maintenance, or relapse.",
      "satisfied": "no",
      "supporting_evidence": [],
      "what_would_cross_it": "Validate cancer/site-specific intervention-caused stage changes against subsequent randomized mortality, including overdiagnosis, lead time and treatment effects; a universal bridge must survive counterexamples."
    },
    {
      "subclaim_id": "SC4",
      "threshold": "Δ",
      "requirement_quoted": "Requires at least one meaningful causal perturbation showing the proposed mechanism contributes to initiation, maintenance, or relapse.",
      "satisfied": "no",
      "supporting_evidence": [],
      "what_would_cross_it": "For each exact MRI or DTC pathway, test a baseline-defined population against usual care with clinical outcomes, downstream procedures and harm ascertainment; enriched hereditary surveillance does not supply general-population equivalence."
    }
  ],
  "generalization_check": {
    "generalization_tested": "yes",
    "context_boundary_mapped": "no",
    "internal_negative_controls": [
      "NHS-Galleri combined stageIII/IV primary endpoint null, PMID42776074",
      "CCGA stageI sensitivity16.8% versus90.1% stageIV, PMID34176681",
      "NHS episode sensitivity26.7–37.2% across all cancers despite high specificity, PMID42773209",
      "UKCTOCS mortality null despite more stageI/fewer stageIV cases, PMID33991479",
      "NordICC incidence benefit with nonsignificant mortality at10/13years, PMID36214590,42102826",
      "Alternative fragmentomics disease controls mimic cancer, PMID40833414",
      "SHIP long-term aggregate QoL/depression null alongside separate transient distress and biopsy/cost reports, PMID26597793,23239059,32860149"
    ],
    "note": "Diagnostic and implementation contexts have been tested, and single-cancer screening outcome boundaries are real. No positive Galleri mortality effect has yet been verified, so these do not map an Ε benefit boundary for the nominal assay. Known-cancer case-control sets, cancer survivors, symptomatic real-world orders, hereditary TP53 surveillance, prenatal abnormal-cfDNA referrals and below50 screening comparators are labelled before outcomes rather than pooled as identical populations."
  },
  "falsification_patterns_met": [],
  "pitfalls_flagged": [
    {
      "pitfall": "A phenomenon graded as though it were a claim",
      "where": "True cancer detection is preserved as descriptive diagnostic evidence. The overall HSEF letter addresses the causal mortality proposition, not whether an assay can detect some cancers."
    },
    {
      "pitfall": "Confirmation by biomarker",
      "where": "Stage, cfDNA signal and predicted five-year survival are not directly observed mortality benefit."
    },
    {
      "pitfall": "Association dressed as mechanism",
      "where": "Earlier-stage prognosis and longer postdiagnosis survival cannot by themselves show screening moved the time of death."
    },
    {
      "pitfall": "Selective generalization",
      "where": "High-risk lung programmes, hereditary TP53 surveillance and selected prenatal referrals do not establish average-risk Galleri or commercial whole-body MRI mortality benefit."
    },
    {
      "pitfall": "Replication confused with reproduction",
      "where": "NHS, CCGA, PATHFINDER, SHIP, NLST, UKCTOCS and NordICC follow-ups are grouped; additional resolution or follow-up is not a new allocation trial."
    },
    {
      "pitfall": "Negative field-valid perturbation read as a crossed threshold",
      "where": "NHS's null primary stage result does not supply a positive clinical crossing merely because allocation was randomized."
    },
    {
      "pitfall": "Causal-evidence tallies that do not survive an audit",
      "where": "No mortality threshold credit is assigned to simulations, diagnostic metrics, other-assay trials, corrections or provider counts."
    },
    {
      "pitfall": "Mechanism conflation",
      "where": "Galleri methylation, CancerSEEK/PETCT, other fragmentomic/protein tests, MRI and germline DTC risk are different tests and pathways."
    }
  ],
  "causal_tally_audit": {
    "tally_claimed_by_document": 0,
    "tally_after_audit": 0,
    "tally_unit": "Positive qualifying study units across scoped subclaims, not independent causal lines or full-claim necessity/sufficiency.",
    "screened_discriminating_contrasts": 4,
    "items_rejected": [
      "Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines.",
      "Zero positive exact Galleri mortality study units are counted; diagnostic performance and stage signals do not become death outcomes.",
      "Single-cancer mortality trials remain comparator context, not nominal-assay threshold credit.",
      "Original validation components count as reports; simulations, reviews, protocols, notices, recruitment/status pages and provider counts do not pad observed clinical efficacy.",
      "The 58 report count is not 58 randomized MCED trials or 58 complete-paper audits."
    ],
    "screened_discriminating_contrasts_note": "Corrected 2026-11-02 (adversarial finding S5) from 5 to 4: randomized allocated-arm contrasts [1], [48], [49] and [51]. [45] is an observational pre/post contrast and [2], [10] and [18] are single-arm descriptive series."
  },
  "steelman": {
    "case_one_rung_higher": "The strongest Δ case notes that Galleri now has a large randomized study, many confirmed asymptomatic detections and a favorable stageIV secondary contrast. For cancers lacking usual screening, an earlier treatable interception could plausibly improve outcomes. Positive mortality trials of other screening pathways demonstrate that the general clinical mechanism can work.",
    "case_one_rung_lower": "The strongest Β case observes that no Galleri mortality result is available and many supporting claims are diagnostic, prognostic or simulated. A mortality-benefit claim based solely on these correlations would remain association-bound. The further case for Α would stress promotion beyond the available clinical endpoint.",
    "which_rejected": "The higher case is blocked by the missing positive exact-assay cancer-death endpoint: a secondary stageIV result and curative treatment intent do not satisfy it. The lower case is rejected because the screening pathway has genuine prospective clinical implementation and randomized perturbation evidence, even though its measured endpoints do not verify mortality benefit. Γ captures partial system support without declaring that detection is false or future mortality benefit impossible.",
    "blocking_cap_threshold_or_missing_experiment": "Missing experiment: Continue or run a randomized intention-to-screen comparison of specified Galleri plus usual care versus usual care in asymptomatic adults≥50, preserving established screening and treatment access. Prespecify cancer-specific mortality, all-cause mortality, site-specific deaths, diagnostic procedures, treatment morbidity, interval cancers and sustained incidence differences over an adequate horizon. Use blinded death adjudication and systematic outcome linkage in both arms. Stage shifts are candidate mediators, with predefined surrogate validation rather than conversion into modeled saved lives."
  },
  "final_score": {
    "hsef_level": "Γ",
    "hsef_descriptor": "Mechanistically plausible, partial system support",
    "confidence": "High",
    "confidence_rationale": "High reflects that the ceiling is well characterised: a large randomized Galleri trial with registry outcomes, a concordant large prospective study and a real-world series all leave no Galleri mortality contrast, so the evidence securely does not justify more than Γ. Other-site mortality trials inform SC3 and the tournament, not Galleri replication. Confidence reflects evidence density and reproducibility, not access depth or correctness, and is in the appraisal, not a prediction of the eventual mortality result.",
    "rests_on_non_peer_reviewed_work": false,
    "rationale": "The preregistered primary-subclaim rule returns Γ from SC2. Fifty-eight original reports were examined, covering Galleri/other MCED diagnostic work, prospective implementation, real mortality-based single-cancer screening comparators, and separate MRI/DTC pathways. No positive Galleri mortality crossing is counted. The current primary stage endpoint failed and a favorable secondary stage IV signal remains; neither proves a mortality benefit or a mortality null. Weakest-link returns Α from the broad companion claim, while primary-subclaim and scope-matched return Γ. The review preserves genuine detections and legitimate established screening benefits without assigning them to a different assay."
  },
  "role_of_mechanism": {
    "classification": "epiphenomenon",
    "derivation_step_matched": 2,
    "derivation": "For the precise mortality-benefit mechanism, no positive clinical mortality dependency is demonstrated in either direction, so Step 2 returns epiphenomenon for that unverified causal account. This does not label the assay biologically inert or claim detections are imaginary; screening changes diagnoses and workups. The label applies to the unestablished saved-lives bridge, not the validity of every cancer signal. The label means that a causal role in reducing cancer deaths is not established by the evidence, not that screening has no effect: no effect of this screening on cancer deaths has yet been shown in either direction, so the label records an unproven link, not a proven absence of effect.",
    "tournament_used_as_tiebreaker": false,
    "note": "Derived from causal direction, not tournament rank.",
    "plain_language_gloss": "No effect of this screening on cancer deaths has yet been shown in either direction; the label records an unproven link, not a proven absence of effect."
  },
  "extended_scoring_MSD": {
    "momentum": {
      "value": "Mechanistic only",
      "artifact": "NHS-Galleri lists cancer-specific mortality up to 8 years as a prespecified secondary outcome (NCT05611632), and the primary report states that cancer-specific and nested mortality will be analysed at 3 and 6 years after the final trial visit, but also that the trial was not powered for mortality endpoints; after the failed primary endpoint its fixed-sequence plan precludes formal testing of secondary outcomes. This follow-up is informative but cannot by itself decisively cross the SC2 threshold. Sources: https://clinicaltrials.gov/study/NCT05611632 ; PMC7619610 (PMID42776074).",
      "justification": "NHS-Galleri lists cancer-specific mortality up to 8 years as a prespecified secondary outcome (NCT05611632), and the primary report states that cancer-specific and nested mortality will be analysed at 3 and 6 years after the final trial visit, but also that the trial was not powered for mortality endpoints; after the failed primary endpoint its fixed-sequence plan precludes formal testing of secondary outcomes. This follow-up is informative but cannot by itself decisively cross the SC2 threshold. Sources: https://clinicaltrials.gov/study/NCT05611632 ; PMC7619610 (PMID42776074)."
    },
    "stability": {
      "value": "Uncertain",
      "trigger": "Prespecified randomized cancer-mortality follow-up could further constrain the exact clinical boundary; current stage results are not that result, and the trial was not powered for mortality endpoints. Named ongoing programme is NHS-Galleri, not an unspecified future study.",
      "justification": "Prespecified randomized cancer-mortality follow-up could further constrain the exact clinical boundary; current stage results are not that result, and the trial was not powered for mortality endpoints. Named ongoing programme is NHS-Galleri, not an unspecified future study."
    },
    "divergence": {
      "implied_level": null,
      "implied_level_basis": "No single field-implied level is defensible from conflicting framings.",
      "assessed_level": "Γ",
      "gap_in_rungs": null,
      "value": "Contested",
      "justification": "No manufactured field consensus or arithmetic gap."
    },
    "calibration_note": "M/S/D never modify HSEF level or confidence."
  },
  "change_record": {
    "applies": false,
    "prior_level": "none assigned",
    "prior_confidence": null,
    "prior_source": null,
    "derived_before_consulting_prior": true,
    "new_level": "Γ",
    "direction": "newly assigned",
    "what_moved_it": "Fresh primary evidence appraisal; not blinded.",
    "divergence_from_other_reviewers": null
  },
  "proposed_decisive_experiments": [
    {
      "name": "Registered boundary experiment",
      "experiment": "Continue or run a randomized intention-to-screen comparison of specified Galleri plus usual care versus usual care in asymptomatic adults≥50, preserving established screening and treatment access. Prespecify cancer-specific mortality, all-cause mortality, site-specific deaths, diagnostic procedures, treatment morbidity, interval cancers and sustained incidence differences over an adequate horizon. Use blinded death adjudication and systematic outcome linkage in both arms. Stage shifts are candidate mediators, with predefined surrogate validation rather than conversion into modeled saved lives.",
      "readout": "Randomized cancer-death effect estimates and intervals, all-cause deaths, site-specific outcomes, interval cancers, diagnostic/treatment harms and excess incidence after sufficient follow-up",
      "critical_control": "Usual-care screening retained, matched invitations/follow-up, prespecified assay versions, blinded outcome review, systematic registry linkage and intention-to-screen analysis",
      "supporting_result": "A replicated lower cancer-mortality rate with net clinical benefit and explicit baseline/site boundaries; diagnostic and treatment pathways support independently validated mediation",
      "falsifying_result": "No meaningful death reduction with adequate exposure, adherence and horizon, or offsetting procedure/treatment harms; favorable stage subsets cannot erase a null or adverse mortality result"
    }
  ],
  "knowledge_gaps": [
    {
      "name": "Gap 1",
      "statement": "Exact Galleri randomized cancer-mortality follow-up rather than surrogate stage outcomes",
      "relevance": "Limits mechanism identification or scope."
    },
    {
      "name": "Gap 2",
      "statement": "Site-specific and assay-version-specific stage-to-mortality validation",
      "relevance": "Limits mechanism identification or scope."
    },
    {
      "name": "Gap 3",
      "statement": "Systematic interval-cancer and false-negative follow-up, especially in real-world use",
      "relevance": "Limits mechanism identification or scope."
    },
    {
      "name": "Gap 4",
      "statement": "Overdiagnosis versus beneficial interception, requiring long-term excess-incidence and outcome assessment",
      "relevance": "Limits mechanism identification or scope."
    },
    {
      "name": "Gap 5",
      "statement": "Diagnostic capacity, patient-level harms and procedure/treatment burden under usual implementation",
      "relevance": "Limits mechanism identification or scope."
    },
    {
      "name": "Gap 6",
      "statement": "Performance transportability across risk, ethnicity, prior cancer and care systems",
      "relevance": "Limits mechanism identification or scope."
    },
    {
      "name": "Gap 7",
      "statement": "Independent general-population MRI and DTC benefit-harm trials rather than hereditary or diagnostic-referral extrapolation",
      "relevance": "Limits mechanism identification or scope."
    }
  ],
  "review_metadata": {
    "review_date": "2026-10-13",
    "reviewer": "Codex",
    "evidence_base_note": "58 primary reports (plus 2 records added in the 2026-11-02 adversarial correction); literature cutoff 2026-10-13; source examination UTC date 2026-10-13; bounded critical review, not exhaustive systematic review.",
    "literature_tools_available": true,
    "literature_tools_note": "Life Sciences Literature PubMed/Entrez, separately logged public original-body retrieval, and Consensus Pro browser searches. Provider output retained as observed browser text with citation-link mappings, or as previously exported connector documents where present. AI synthesis is not primary full-text verification. Consensus retrieved/included counts are not examined-primary counts. Scite monthly limit was reached earlier in this session; no new Scite query or incoming citation-context audit is claimed for these cases. Tool receipts record actual use. Supplementary discovery outputs do not earn primary-count credit. No independent blinded review.",
    "skill_version": "5.3",
    "validator_run": "PASS: exact archived HSEF v5.3 validator rerun after final sealing.",
    "validator_warnings_addressed": "No warnings.",
    "limits": "Bounded source-based critical review; no complete-paper/supplement audit, independent scientific peer review or blinded calibration. Revision cases retain original prose outside the three framework output blocks and have explicit correction logs.",
    "authorship_of_record": "Codex (OpenAI), per review_metadata.reviewer and provenance_header.generated_by; the 'Sol 6.1' header label is a house label and no specific model version is inferred (reconciled 2026-11-02, adversarial finding S11).",
    "adversarial_review": [
      {
        "date": "2026-10-14",
        "reviewer": "Claude Opus 5.5 (Anthropic)",
        "findings": "M1-M4",
        "status": "corrections applied"
      },
      {
        "date": "2026-11-02",
        "reviewer": "Claude Opus 5.5 (Anthropic)",
        "findings": "S1-S11",
        "corrections_applied_on": "2026-11-02",
        "authorised_by": "principal investigator",
        "level_after": "Γ",
        "confidence_after": "High",
        "records": [
          "ADVERSARIAL_REVIEW.mced-cancer-mortality.md",
          "adversarial-findings.mced-cancer-mortality.json",
          "validation-round3-2026-11-02.json"
        ]
      }
    ],
    "redteam_reviewed": true
  },
  "is_calibration_entry": {
    "value": false,
    "entry_role": "not_calibration",
    "blind_graded": null,
    "completed_blinded_calibration": false,
    "expected_band_sealed_at": "",
    "target_sha256": "",
    "target_authorship": "not applicable",
    "target_author_saw_review": null,
    "future_run_status": "not prepared",
    "unblinded_reason": "These topic families were selected from an editorial traffic-priority list. Selection was visible; no blind calibration or predetermined clinical verdict was preregistered."
  },
  "upper_ladder_check": {
    "final_level_below_zeta": true,
    "equivalents_considered": [
      {
        "kind": "mendelian_randomization",
        "available": false,
        "why_not_sufficient": "Randomized clinical screening is a valid prophylactic perturbation equivalent, and multiple other-site trials were evaluated. None provides a positive exact Galleri mortality contrast. Dose-response, observational survival and model predictions do not independently exclude lead time, ascertainment or overdiagnosis. No exposure-specific genetic natural experiment supplies the clinical bridge. A genuinely complementary same-scope set would be considered together rather than capped by its weakest observational leg."
      },
      {
        "kind": "natural_experiment",
        "available": false,
        "why_not_sufficient": "Randomized clinical screening is a valid prophylactic perturbation equivalent, and multiple other-site trials were evaluated. None provides a positive exact Galleri mortality contrast. Dose-response, observational survival and model predictions do not independently exclude lead time, ascertainment or overdiagnosis. No exposure-specific genetic natural experiment supplies the clinical bridge. A genuinely complementary same-scope set would be considered together rather than capped by its weakest observational leg."
      },
      {
        "kind": "dose_response_across_populations",
        "available": false,
        "why_not_sufficient": "Randomized clinical screening is a valid prophylactic perturbation equivalent, and multiple other-site trials were evaluated. None provides a positive exact Galleri mortality contrast. Dose-response, observational survival and model predictions do not independently exclude lead time, ascertainment or overdiagnosis. No exposure-specific genetic natural experiment supplies the clinical bridge. A genuinely complementary same-scope set would be considered together rather than capped by its weakest observational leg."
      },
      {
        "kind": "withdrawal_rechallenge",
        "available": false,
        "why_not_sufficient": "Randomized clinical screening is a valid prophylactic perturbation equivalent, and multiple other-site trials were evaluated. None provides a positive exact Galleri mortality contrast. Dose-response, observational survival and model predictions do not independently exclude lead time, ascertainment or overdiagnosis. No exposure-specific genetic natural experiment supplies the clinical bridge. A genuinely complementary same-scope set would be considered together rather than capped by its weakest observational leg."
      },
      {
        "kind": "therapeutic_perturbation_hard_endpoint",
        "available": false,
        "why_not_sufficient": "Randomized clinical screening is a valid prophylactic perturbation equivalent, and multiple other-site trials were evaluated. None provides a positive exact Galleri mortality contrast. Dose-response, observational survival and model predictions do not independently exclude lead time, ascertainment or overdiagnosis. No exposure-specific genetic natural experiment supplies the clinical bridge. A genuinely complementary same-scope set would be considered together rather than capped by its weakest observational leg."
      }
    ],
    "convergence_present": false,
    "cap_reapplied_to_convergent_set": false
  },
  "provenance_header": {
    "sources_total": 60,
    "claims_total": 65,
    "claims_verified": 65,
    "claims_unverified": 0,
    "claims_contradicted": 0,
    "tier_a_sources": 59,
    "generated_by": "Codex; HSEF v5.3",
    "gate_passed": true
  },
  "claims": [
    {
      "id": "C1",
      "text": "NHS-Galleri randomized 142250 adults 50–77 to tested versus stored blood plus usual care for 3 annual rounds; primary stage III/IV incidence IRR 1.03, 95% CI 0.92–1.14, P=.63; key secondary stage IV IRR 0.86, 95% CI 0.74–1.00, not formally tested under the fixed-sequence plan and with an unadjusted interval; the stage IV decrease (341 vs 394) was offset by more stage III cancers (360 vs 287), and the secondary stage III/IV-or-fatal composite was null (IRR 1.04, 0.97–1.12; PMC7619610). Primary proxy failed, secondary signal retained; no mortality result in this publication. Neither randomized design nor a stage IV contrast supplies a positive cancer-mortality crossing. Publisher abstract verified 22 September 2026; full-body access not claimed.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC2",
        "SC3"
      ],
      "source_ns": [
        1
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C2",
      "text": "Same NHS trial descriptive test-performance report across3rounds:937detectedprimary cancers, PPV58.0/50.4/45.8%, all-cancer episode sensitivity26.7–37.2%, specificity99.5–99.6%. Descriptive intervention-arm diagnosis metrics without hypothesis testing; not an independent randomized trial or mortality analysis. High NPV largely reflects low prevalence and does not mean every cancer is excluded.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC2"
      ],
      "source_ns": [
        2
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C3",
      "text": "Original NHS recruitment analysis1.5million invitations/142924 enrolled; older/deprived groups enriched but Black/Asian groups underrepresented despite targeting. Same parent trial, recruitment denominators differ from final randomized142250. Sociodemographic reach does not establish efficacy, and enrollment composition limits transportability.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC2"
      ],
      "source_ns": [
        3
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C4",
      "text": "Original NHS operational report describes nurse referral into56Trusts with CSO-guided pathways and safety-netting. Implementation feasibility and coordination are meaningful but not mortality benefit, diagnostic accuracy estimates or a separate efficacy trial.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC2"
      ],
      "source_ns": [
        4
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C5",
      "text": "CCGA/STRIVE case-control training/validation cfDNA methylation; specificity99.3%, all-cancer stageI sensitivity18% rising to93%stageIV. Known-cancer versus control design and version differ from population screening; sensitivity increases with burden. Detection feasibility does not validate stage-to-mortality benefit.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC3"
      ],
      "source_ns": [
        5
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C6",
      "text": "CCGA independent validation4077 participants including2823known cancers; specificity99.5%, overall sensitivity51.5%, stageI16.8%, tissueorigin88.7%. Case-control spectrum/prevalence differs from asymptomatic screening; independent validation set is not an independent mortality perturbation. Stage-specific sensitivity is descriptive.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC3"
      ],
      "source_ns": [
        6
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C7",
      "text": "CCGA1 compares10cfDNA classifiers at98%specificity; tumor allele fraction predicts detection and methylation localizes origin. Same assay-development samples; classifier optimization and limit of detection do not show clinical utility, treatment benefit or prospective-screening accuracy.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        7
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C8",
      "text": "CCGA tumor-fraction models relate breast/lung tumor mitotic or metabolic volume and colorectal invasion to cfDNA and validate inCCGA2. Biological correlation may explain preferential detection of aggressive cancers; it does not establish that detected cancers are treatable earlier or that overdiagnosis is absent.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC3"
      ],
      "source_ns": [
        8
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C9",
      "text": "CCGA3 descriptive racial/ethnic analysis uses same4077validation participants; specificity high across groups with some small subgroup samples. Exploratory subgroup intervals and predominantlyWhite cohort limit broad equivalence claims; no independent efficacy trial or mortality result.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        9
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C10",
      "text": "PATHFINDER convenience cohort≥50 without cancer symptoms:6621 analyzable;92signals,35confirmed,57falsepositives; false-positive diagnostic resolution median162days and30%procedures. Single-arm feasibility primary endpoint is diagnostic workup, not mortality. A low overall false-positive rate and62%false-positive share among signals are different denominators. Attempted originalXML returned500; abstract examined.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC2",
        "SC4"
      ],
      "source_ns": [
        10
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C11",
      "text": "DETECT-A prospective blood-test/PETCT pathway10006women found26cancers by blood;24 by routine screening and46neither;0.22%futile invasive procedures. Different assay plusPETCT package, no randomized mortality control. Curative-intent surgery is not proven cure or mortality reduction; routine screening remains complementary. PublicXML failed500.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC2",
        "SC4"
      ],
      "source_ns": [
        11
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C12",
      "text": "Alternative fragmentomics assay validated in separate known-cancer cohorts and preliminary3724asymptomatic cohort with53.5%sensitivity/98.1%specificity. Not Galleri; case-control high sensitivity falls in screening context. Clinical decision potential and cancer detection do not prove survival benefit.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        12
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C13",
      "text": "ORF1p ultrasensitive plasma protein assay identifies multicancer and precursor signals, with prognostic associations and response monitoring. Alternative biomarker, not Galleri or randomized early detection. Original correction39228301 restores a compositor-omitted ovarian tissue-expression pie chart in Fig1D; no changed detection result is specified. Biomarker detection is not a mortality crossing.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        13
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C14",
      "text": "THUNDER original case-control independent505cancer/505control validation of6cancer methylation panel showed69.1%sensitivity/98.9%specificity. Predicted late-stage decline and survival gains are simulations, not observed intervention outcomes; new original diagnostic component alone earns report credit. Assay differs from Galleri.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC3"
      ],
      "source_ns": [
        14
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C15",
      "text": "AlternativePSpositive vesicle assay1869clinical samples and3validation cohorts; early-stage sensitivity74.7% with89.8%specificity; cells/mice support marker biology. Known-cancer cohort spectrum and relativelylower specificity may matter at lowprevalence; no Galleri inference, asymptomatic mortalitytrial or demonstrated curative benefit.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        15
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C16",
      "text": "ARIC26cases/26controls with storedserialplasma;4of6assessable earlier samples contained same mutations3.1–3.5years before diagnosis at muchlowerfraction. Verysmall nested case-control detection benchmark; retrospective earlier-sample interrogation is not prospective clinical intervention or proof that years-earlier treatment prevents death.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC3"
      ],
      "source_ns": [
        16
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C17",
      "text": "AlternativePCRmethylation panel103diverse cancer cases/40healthy controls showed47.6%sensitivity/90%specificity. Background sentence asserting all-cause mortality reduction is not a study result; no mortality endpoint or population screening. Small proof-of-concept rather than Galleri validation.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC2"
      ],
      "source_ns": [
        17
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C18",
      "text": "OriginalM/R:111080real-world tests≥22,1011signals;voluntary outcomes459,48ongoingworkups,411complete. Asymptomatic completed subset128/259invasive cancers, ePPV49.4%; negatives not systematically followed. Symptomatic/active-cancer uses and incompletepositive follow-up preclude fullpopulation sensitivity, universalPPV or mortality claims. Large testcount is not completeclinical ascertainment or screening-only cohort.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC2"
      ],
      "source_ns": [
        18
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Results:paragraph5, 1:Results:paragraph6, 1:Results:paragraph12, 1:Results:paragraph13, 3:Methods:paragraph1, 3:Methods:paragraph2, 3:Methods:paragraph3, 3:Methods:paragraph4. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C19",
      "text": "SPOTMAS methylomics/fragmentomics738nonmetastatic cancercases/1550healthy controls;72.4%sensitivity at97%specificity; stage-dependent results. Alternative assay case-control training/validation, not population predictivevalues or mortality benefit. UpdateOf notices carry no suppliedPMIDs and are retained as version-history uncertainty.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        19
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C20",
      "text": "LINE1 hypomethylation classifiers747samples in2independent cohorts distinguish6cancer plasmas withhighAUC. Different reference-free assay; AUC across selectedclinical cohorts is not lowprevalence screeningPPV or clinicalmortality benefit.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        20
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C21",
      "text": "SerummiRNA training2800plus and independentlarge case-controlvalidation yields veryhigh reportedsite-specific sensitivity/specificity. Platform, batch/spectrum and control selection needprospective transportability checks; independent assay validation is not assignedscreening benefit or Galleri performance.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        21
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C22",
      "text": "413cancer/239healthy plasmaeccDNA data plusPDXfragment model trainScanTecc; cancerclassificationAUC.92 andoriginAUC.79. Exploratory assay andin-silicofragment selection cannot establish clinicalutility, populationPPV or benefit; PDXmechanism does not supplyscreeningmortality evidence.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        22
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C23",
      "text": "FreeGAGprofiles original1260subjects andvalidation screening-like121/49cases showlower firststage detection at≥99%specificity; undetectedcancers havebetter prognosis. Detection correlateswith risk but doesnot show screening reduces deaths; prognostic selection and known-case sampling constrain survival claims. Alternativeassay notGalleri.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC3"
      ],
      "source_ns": [
        23
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C24",
      "text": "NovelddPCR promoterpanel485plasmas andtissuedata achieves60.1%sensitivity/87.4%specificity across4majorcancers. Lowprevalence falsepositive implications, smallproof-of-concept andotherassay identity limit population screening; no clinicaldeathendpoint.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        24
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C25",
      "text": "GUIDEGutSeer originaltraining/validation andlocked846person independentGIcohort shows~81.5%sensitivity/94.4%specificity andprecancer detection. Mixedin/outpatient knownGIcases andnew assay, notGalleri ormortalityscreening trial; stage detection not benefit proof.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        25
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C26",
      "text": "KDETEK9057asymptomatic≥40Vietnam;9024eligible,43signals,17malignancies,PPV39.5%, one-yearnegative follow-up; TOO52.9%. Smallcancercount and12monthascertainment constrain estimates; alternativeSPOTMASandage40scope differ. Originalcallsutility butdoesnot measuremortality utility.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC2"
      ],
      "source_ns": [
        26
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C27",
      "text": "Originalfragmentomics study showsvenousthromboembolism/autoimmune profiles resemblecancer andproducefalsepositives underbinaryclassifiers; addingproteins/multiclassapproach improves discrimination. Specificity challenge to this assay class, not direct evidence against Galleri methylation specificity. Original correction41628341 adds funding acknowledgments rather than numerical results. No mortality endpoint was measured.",
      "carries_number": false,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        27
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C28",
      "text": "Alternative16proteinclassifier141knowncancercases/119healthy controls reports100%sensitivity and97%specificity. Small case-control model development cannot establish prospective screening100% sensitivity or survival benefit. Original correction41595793 changes male breast percentage to3.3% and specificity95%CI to90–99% for breast and92–99% for lung; authors state conclusions unchanged. This is not Galleri.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        28
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C29",
      "text": "EVproteinpilot139pathologyconfirmed stageI/IIcases versus184controls; sensitivity71.2% at99.5%specificity withlarge cancersitedifferences. Selectedcase-control pilot, different3cancerassay; earlystage discrimination is notclinicalscreeningbenefit orallcancerperformance.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        29
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C30",
      "text": "PATHFINDER1609survivor subgroup,20signals and10newdiagnoses includingsecondprimaries/recurrences;testmetrics describedsimilar. Sameparentcohort; survivorsdiffer fromaverage-riskfirstscreening andno randomsurvival comparison. Added subgroups do notcreateefficacyreplication.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC2"
      ],
      "source_ns": [
        30
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C31",
      "text": "PATHFINDERPROsecondary study foundtransienthigheranxiety aftersignals,meanreturn towardbaseline by12months andhighsatisfaction; response counts differ bygroup/time. Sameparenttrial andmissing questionnaires; averages/satisfaction cannotexcludeindividualdistress orprove netmortalitybenefit. No randomscreeningpsychosocialcontrol.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC4"
      ],
      "source_ns": [
        31
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C32",
      "text": "41selectedNHSsignal-positive interviewees describeexpectations,uncertainty andreassurance differences with/withoutcancer. Purposivequalitative subset notincidenceofharm orcausal mortalityevidence; sameNHSparent, self-reportedcancerstatus.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC4"
      ],
      "source_ns": [
        32
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C33",
      "text": "53Britishadults50–77 focusgroups expressenthusiasm foreasybloodscreening andconcernaboutfalsepositives/followupprocedures. Beliefsaboutreduceddeaths areparticipants'views ratherthanevidence; hypotheticalacceptability notactualscreeningbenefit/harmrate.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC4"
      ],
      "source_ns": [
        33
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C34",
      "text": "IDENTIFY selected107pregnant/postpartumunusualprenatalcfDNAresults;52occultcancers, WBMRIsensitivity98% andspecificity88.5%; certaincopy-numberpatternstronglypredictive. Extremelyenrichedabnormaltestreferredpopulation andpregnancy context; notgeneralpopulationMRI/Galleri screeningperformance or mortalityreduction.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC4"
      ],
      "source_ns": [
        34
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C35",
      "text": "CancerSEEK1005clinicallydetectednonmetastatic cancers/812healthy controls showedmedian70%detection and>99%specificity. Differentmutation/proteinassay andknowncasecontrol design; no asymptomaticprospective ormortalitycomparison. Detectionlocalization notcure.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        35
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C36",
      "text": "PanSeerstoredTZLplasma605asymptomatic subjects including191subsequentcancers showedprediagnostic signals up to4years;223postdiagnosiscases alsoassayed. Nestedselectedstoredsamples do notestablish liveclinicalscreening intervention or mortalitybenefit; prospectiveconfirmation required, notGalleri.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC3"
      ],
      "source_ns": [
        36
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C37",
      "text": "89TP53carrierschosecomprehensivesurveillance ornot;19crossedover;59under surveillance,5yearpostdiagnosissurvival88.8%vs59.6%,falsepositives/negativesoccurred. As-treatedselfselection,leadtime andmulti-modalitybundle inhighrisk hereditary families; notisolatedMRIcausalbenefit or generalaverage-riskcommercialscreening.",
      "carries_number": true,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        37
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C38",
      "text": "SWEP53baseline61adultTP53carriers;19furtherworkups,3asymptomatic malignancies;dedicatedbrain/breastimagingincluded. Highriskhereditarysurveillance andsinglebaseline yield; no assignedmortalitycontrast orall-comercommercialMRIequivalence.",
      "carries_number": true,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        38
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C39",
      "text": "SHIPTrend4420participants/2188MRI;2.5year follow-upfoundnegligibleoverallQoL/depressiondifferences withMRIorincidentaldisclosures. OptionalMRIparticipation andattritionweighting; overallpsychosocialnulldoesnot establish clinicalbenefit or ruleoutshort-term/individualdistress.",
      "carries_number": true,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        39
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C40",
      "text": "SHIP5019withinsurance,2969MRI,propensityweightednonparticipants; incidentalfindings32%,outpatientcosts about€295/11.6%higher over2years. Quasiexperimentalnotrandomized, MRIplusclinicalworkupandselectionmayconfound; costsarenotautomaticallymedicalharms andnocancermortalitybenefitcomparison.",
      "carries_number": true,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        40
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C41",
      "text": "Retrospective75LFSadultstotal325WBscans;9of17cancersMRI-detected,89scansbenignincidentalfindingsprompted53investigations;sensitivity42.9%. HighlyselectedTP53surveillance ratherthangeneralpopulation,DTCorGalleri; repeatedscans/subjects notindependentcases andno controlledmortalityendpoint.",
      "carries_number": true,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        41
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C42",
      "text": "148healthyresearchvolunteers,29.1%abnormalWBscans,12.8%clinicallysignificantfindings; prevalencehigherwithage/BMI. Researchcohortmedian36 andsinglehospital; clinicalsignificancelabelnot provennetbenefit or mortalityprevention. No comparisonintervention.",
      "carries_number": true,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        42
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C43",
      "text": "118consecutiveasymptomatichealthcheckparticipants;103benignlesionsin83subjects,2malignantand1precancerouslesionfound. Detectionyield andanatomiccoverage notmortality/netbenefit; selectedhealthcheckcohort andsmall malignancydenominator.",
      "carries_number": true,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        43
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C44",
      "text": "SHIP2500WBMRI;36.2%potentiallyrelevantincidentalfindings,31.5%disclosed,mostnatureunclear;9urgentreferrals. Reader/advisoryclassification isnotfullyconfirmedmalignancy; extraorganimagingin subsets andsharedSHIPparticipants requiregrouping. No mortalitytrial.",
      "carries_number": true,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        44
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C45",
      "text": "OriginalM/RSHIP6753participants withoptionalMRI3371; linkedbiopsyrate6.9pre to9.9post per100observationyears;largeabsoluteincrease innonmalignantresults, higherwithdisclosedMRI/labfindings. Concurrentlabdisclosures,selection andregionalpathologycoverage constrainMRI-specificcausation; increasedbiopsiesdonot quantifyoverdiagnosisorproveallMRI net harm. No randomizedmortalitycontrast.",
      "carries_number": true,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        45
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph10, 1:Methods:paragraph23, 2:Results:paragraph1, 2:Results:paragraph7, 2:Results:paragraph14. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C46",
      "text": "405SHIPincidental-finding surveyrespondents;28.6%moderate/severedistressafterdisclosure despite96%satisfaction;subjective/radiologicalseverityagreementlow. Selecteddisclosedrespondents,no randomcounterfactual andsameSHIPparent; acuteharm/satisfactionarenot universalorlongtermnetbenefitmetrics.",
      "carries_number": true,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        46
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C47",
      "text": "49clinicalconfirmationreferralsfromDTCrawdata/thirdpartyinterpretation;40%reportedvariantsfalsepositive andsomeincreased-risklabelsclinicallybenign. Referral-enrichedvariantdenominator; doesnot mean40%ofallDTCcustomersortestsarewrong. GeneticriskinterpretationnotMCEDdiagnosisandnotclinicalmortalitytrial.",
      "carries_number": true,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        47
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C48",
      "text": "NLST53454highrisksmokers randomized3annualLDCTvschestradiography; lungcancermortality20%relativeandallcause6.7%lower atinitialfollow-up,withmanypositive-screenfalsealarms. Positive disease-specificscreeningmortalityproof indefinedrisk/context, notGalleri; higherincidenceandprocedureharms mustremain. Differentmodalitycannot supplyexactleadthreshold.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        48
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C49",
      "text": "NELSONrandomizedhighrisksmokers50–74 tovolumetricCT/noscreening;10yearmale lungdeathRR.76CI.61–.94, women.67CI.38–1.14. Truepositiveclinicalscreeneffect indefinedpopulation; sexsubgroupimprecise, differenttest/site/carepathway. NoMCEDmortalitycrossing.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        49
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C50",
      "text": "SameNLSTextendedmortalitymedian12.3years;lungdeathRR.92CI.85–1.00,dilutionadjusted.89;NNS303,allcauseintervalincludesnull. Longerhorizonaltersestimates; repeatedparentfollow-upnotindependenttrialor evidenceforallcancer bloodscreens.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        50
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C51",
      "text": "Original M/R UKCTOCS 202562 average-risk women 50–74, median 16.3 years; MMS increased stage I 47.2% and reduced stage IV 24.5%, but ovarian/tubal deaths not lower P=.58; USS P=.36. Direct stage/mortality dissociation blocks universal surrogate claim; does not prove Galleri mortality null because assay/site differ. Positive clinical mortality crossing absent for ovarian programme. The combined stage III/IV reduction (10.2%, 95% CI −21.3 to 2.4) was not significant, so the dissociation is stage IV-only.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        51
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph4, 1:Methods:paragraph8, 1:Methods:paragraph11, 2:Results:paragraph3, 2:Results:paragraph11, 2:Results:paragraph16. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C52",
      "text": "UKCTOCSoriginalcomprehensivefollow-upretainsmortalitynull andstagechanges; unnecessaryfalsepositive surgery2.3perMMSscreen-detectedcase and10perUSSdetectedcase. Sameparenttrialanddenominatorsnotper-personrisk; no independentRCT ordirectGalleri harmsrates. Thisisoriginaltrialreport,notprotocol.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC3",
        "SC4"
      ],
      "source_ns": [
        52
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C53",
      "text": "CAP415357men50–69clusterinvitationPSA;15yearsecondary prostate-deathRR.92CI.85–.99,absoluterisk.69%vs.78%;lowgrade/localizeddetectionincreased,allcauseeffectnonsignificant. Original10yearprimarynulland15yearsecondaryresultbothmatter; differentorgan,testsandinvitationnotGalleri. Absoluteeffectsmallanddiagnostic/treatmentdeathsreported.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        53
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C54",
      "text": "NordICC84585adults55–64 randomizedinvitationcolonoscopy/usualcare;42%uptake;10yearincidenceRR.82positive,deathRR.90CI.64–1.16null;15majorbleeds. Invitationsharedcareeffect differsfromprocedureefficacy amongcompliers; incidencebenefitdoesnotbyitselfestablishmortalitybenefit. NoGalleriinference.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        54
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C55",
      "text": "SameNordICC13yearfollow-up incidencebenefit andcancerdeathRR.88CI.68–1.08;lowercontrolmortalitythanexpectedmayreducepower. No significantmortalitycontrast,perprotocolnonrandomadherencesensitive;Erratum42119586attached. AvoiduncorrectedfinegrainsubgroupCIwhichabstractformatsanegativeupperbound.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        55
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C56",
      "text": "ERSPC23yearfollow-up core162236men55–69randomizedPSAinvitation; prostate-deathRR.87CI.80–.95,absolutereduction.22%,incidencehigher1.30. Truepositiveparticularscreeningcontext butoverdiagnosisremains,notGallerioreverycancer. AttachedErratum41812212needsdetailcheck; notdirectMCEDmortalityevidence.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        56
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C57",
      "text": "UKAge160921women randomizedmammography39–41through48orusualage50screen;10yearbreastdeathRR.75positive,laterintervalRR.98null. BelowregisteredGalleriageatbaseline anddifferentassay; timinganddisease-specificboundarycontext only,notexactleadclinicalcrossingorproofallstagechangesbenefit.",
      "carries_number": true,
      "load_bearing_for": [
        "SC2",
        "SC3"
      ],
      "source_ns": [
        57
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C58",
      "text": "UKLSpilot4055highriskadults50–75randomizedCT/usualcare;42detectedcancers,85.7%stage1/2;temporarydistressandcostmodelreported. Pilotfeasibilitywithsurrogate/costmodel,notactualmortalitycomparisonatthisreport; don'tborrowNLSTdeathbenefitorthisstageyieldforGalleri.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC2",
        "SC3"
      ],
      "source_ns": [
        58
      ],
      "verification": "verified",
      "verified_against": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "C59",
      "text": "PATHFINDER 2 prospective single-arm study, 35,878 enrolled adults ≥50 without clinical suspicion of cancer; among 32,007 performance-analyzable participants, detection rate 0.54%, PPV 60.3%, episode sensitivity 39.3% (69.8% for 12 prespecified cancers), specificity 99.64%; 213 of 35,335 safety-analyzable participants (0.6%) had invasive procedures after a positive test. Descriptive endpoints without hypothesis testing and no comparator arm; no mortality endpoint. The authors state that randomized trials and longer follow-up are needed to assess clinical utility. Strengthens the SC1 and harms record; does not address SC2.",
      "carries_number": true,
      "load_bearing_for": [
        "SC1",
        "SC4"
      ],
      "source_ns": [
        59
      ],
      "verification": "verified",
      "verified_against": "Bounded original abstract and PubMed metadata examined 2026-11-02 during the adversarial correction; no complete-paper or supplement audit claimed.",
      "verified_on": "2026-11-02",
      "note": "Added in the 2026-11-02 adversarial correction (S7)."
    },
    {
      "id": "C60",
      "text": "A systematic review and meta-analysis of randomized cancer-screening trials found that the correlation between reductions in late-stage incidence and in cancer-specific mortality varies by cancer type, high for ovarian and lung and weak for colorectal and prostate, so stage-surrogate validity is site specific. Tier B synthesis: frames SC3 but does not carry an experimental number; does not include a Galleri or MCED mortality result and does not validate a multi-cancer stage surrogate.",
      "carries_number": false,
      "load_bearing_for": [
        "SC3"
      ],
      "source_ns": [
        60
      ],
      "verification": "verified",
      "verified_against": "Bounded original abstract and PubMed metadata examined 2026-11-02 during the adversarial correction; no complete-paper or supplement audit claimed.",
      "verified_on": "2026-11-02",
      "note": "Added in the 2026-11-02 adversarial correction (S6); Tier B frames but carries no experimental number."
    },
    {
      "id": "CSC1",
      "text": "Prospective Galleri studies and the NHS intervention-arm performance report demonstrate genuine cancer detections with quantified false positives, missed cancers and tissue-origin guidance. Diagnostic accuracy is reported descriptively, not as a causal grade on whether detection exists. The helper-compatible Γ entry records the unbridged inference from that diagnostic signal to meaningful clinical benefit, not doubt that the test detects some cancers. Case-control sensitivity differs from screening performance and cannot be substituted into population benefit estimates.",
      "carries_number": false,
      "load_bearing_for": [
        "SC1"
      ],
      "source_ns": [
        1,
        2,
        3,
        4,
        5,
        6,
        7,
        8,
        9,
        10,
        11,
        12,
        13,
        14,
        15,
        16,
        17,
        18,
        19,
        20,
        21,
        22,
        23,
        24,
        25,
        26,
        27,
        28,
        29,
        30,
        31,
        32,
        33,
        34,
        35,
        36,
        58,
        59
      ],
      "verification": "verified",
      "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "CSC2",
      "text": "No examined primary report provides a positive randomized Galleri cancer-mortality contrast. The 2026 NHS trial randomized 142250 adults aged 50–77; its primary stage III/IV endpoint was null, while the stage IV secondary contrast was favorable. These are stage endpoints, not deaths. Official trial information states that mortality follow-up continues; the trial was not powered for mortality endpoints. Detection, feasibility, reported treatment and favorable stage subsets cannot cross the registered mortality threshold. Γ reflects plausible partial clinical system support with an unverified mortality bridge, not proof that a mortality trial has refuted Galleri.",
      "carries_number": false,
      "load_bearing_for": [
        "SC2"
      ],
      "source_ns": [
        1,
        2,
        3,
        4,
        10,
        11,
        17,
        18,
        26,
        30,
        48,
        49,
        50,
        51,
        52,
        53,
        54,
        55,
        56,
        57,
        58
      ],
      "verification": "verified",
      "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "CSC3",
      "text": "A stage shift is insufficient by itself to establish saved lives. UKCTOCS directly demonstrates more stage I and fewer stage IV ovarian/tubal diagnoses without a cancer-mortality reduction after 16.3 years. Across 41 screening RCTs, late-stage incidence reductions tracked mortality closely for ovarian and lung cancer but weakly for colorectal and prostate cancer (PMID38583868); UKCTOCS's combined stage III/IV change was not significant, so its dissociation is a stage IV-only one, the same pattern as NHS-Galleri. NHS-Galleri's stage IV secondary signal is retained, but the combined stage III/IV primary endpoint was not met. Site-specific biology, lead time, overdiagnosis, treatment and competing mortality require direct validation; stage-to-mortality causal inference retains Γ.",
      "carries_number": false,
      "load_bearing_for": [
        "SC3"
      ],
      "source_ns": [
        1,
        5,
        6,
        8,
        14,
        16,
        23,
        36,
        48,
        49,
        50,
        51,
        52,
        53,
        54,
        55,
        56,
        57,
        58,
        60
      ],
      "verification": "verified",
      "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "CSC4",
      "text": "General-population full-body MRI and DTC testing lack a verified comparable net mortality benefit in the examined sources. MRI detects real lesions and some cancers, while incidental findings, investigations, costs and distress also occur. Hereditary TP53 surveillance and abnormal prenatal cfDNA workup are enriched contexts and different packages. A selected DTC confirmation series identifies false variants without implying40% of all consumer tests are wrong. Blanket clinical-benefit equivalence remains Α.",
      "carries_number": false,
      "load_bearing_for": [
        "SC4"
      ],
      "source_ns": [
        10,
        11,
        31,
        32,
        33,
        34,
        37,
        38,
        39,
        40,
        41,
        42,
        43,
        44,
        45,
        46,
        47,
        52
      ],
      "verification": "verified",
      "verified_against": "Synthesis of examined primary result/limit cards; framework level is adjudication.",
      "verified_on": "2026-10-13",
      "note": ""
    },
    {
      "id": "CH",
      "text": "Galleri detects real cancers, but a cancer-mortality benefit remains unestablished; the 2026 primary stage endpoint was null and a lower stage IV rate in a secondary endpoint that could not be formally tested requires clinical follow-up.",
      "carries_number": false,
      "load_bearing_for": [
        "SC2"
      ],
      "source_ns": [
        1,
        2,
        10,
        51
      ],
      "verification": "verified",
      "verified_against": "Bounded synthesis of examined sources; score is adjudication.",
      "verified_on": "2026-10-13",
      "note": ""
    }
  ],
  "citation_ledger": [
    {
      "n": 1,
      "citation": "Sasieni P, Johnson P, Round T et al. Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis. The New England journal of medicine. 2026.",
      "tier": "A",
      "kind": "rct",
      "pmid": "42776074",
      "doi": "10.1056/NEJMoa2505723",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42776074/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "NHS_Galleri_NCT05611632",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. Adversarial pass 2026-11-02 examined the PMC author manuscript (PMC7619610) for secondary-endpoint testing status, stage III and IV counts, the fatal-cancer composite and the mortality-power statement.",
      "carries_claims": [
        "C1",
        "CSC1",
        "CSC2",
        "CSC3",
        "CH"
      ]
    },
    {
      "n": 2,
      "citation": "Neal RD, Dolly S, Johnson P et al. Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial. Nature medicine. 2026.",
      "tier": "A",
      "kind": "secondary_trial_diagnostic_report",
      "pmid": "42773209",
      "doi": "10.1038/s41591-026-04652-8",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42773209/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "NHS_Galleri_NCT05611632",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C2",
        "CSC1",
        "CSC2",
        "CH"
      ]
    },
    {
      "n": 3,
      "citation": "Swanton C, Bachtiar V, Mathews C et al. NHS-Galleri trial: Enriched enrolment approaches and sociodemographic characteristics of enrolled participants. Clinical trials (London, England). 2025.",
      "tier": "A",
      "kind": "original_trial_enrollment_analysis",
      "pmid": "39862108",
      "doi": "10.1177/17407745241302477",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39862108/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "NHS_Galleri_NCT05611632",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C3",
        "CSC1",
        "CSC2"
      ]
    },
    {
      "n": 4,
      "citation": "Lowenhoff I, Dolly S, Dowinton Smith R et al. Clinical referral to the NHS following multi-cancer early detection test results from the NHS-Galleri trial. Frontiers in oncology. 2025.",
      "tier": "A",
      "kind": "original_implementation_report",
      "pmid": "40406252",
      "doi": "10.3389/fonc.2025.1511816",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40406252/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "NHS_Galleri_NCT05611632",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C4",
        "CSC1",
        "CSC2"
      ]
    },
    {
      "n": 5,
      "citation": "Liu MC, Oxnard GR, Klein EA et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Annals of oncology : official journal of the European Society for Medical Oncology. 2020.",
      "tier": "A",
      "kind": "primary",
      "pmid": "33506766",
      "doi": "10.1016/j.annonc.2020.02.011",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33506766/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "CCGA_STRIVE_assay_development",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C5",
        "CSC1",
        "CSC3"
      ]
    },
    {
      "n": 6,
      "citation": "Klein EA, Richards D, Cohn A et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Annals of oncology : official journal of the European Society for Medical Oncology. 2021.",
      "tier": "A",
      "kind": "primary",
      "pmid": "34176681",
      "doi": "10.1016/j.annonc.2021.05.806",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34176681/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "CCGA3_NCT02889978",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C6",
        "CSC1",
        "CSC3"
      ]
    },
    {
      "n": 7,
      "citation": "Jamshidi A, Liu MC, Klein EA et al. Evaluation of cell-free DNA approaches for multi-cancer early detection. Cancer cell. 2022.",
      "tier": "A",
      "kind": "original_assay_comparison",
      "pmid": "36400018",
      "doi": "10.1016/j.ccell.2022.10.022",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36400018/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "CCGA1_NCT02889978",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C7",
        "CSC1"
      ]
    },
    {
      "n": 8,
      "citation": "Bredno J, Lipson J, Venn O et al. Clinical correlates of circulating cell-free DNA tumor fraction. PloS one. 2021.",
      "tier": "A",
      "kind": "original_tumor_fraction_analysis",
      "pmid": "34432811",
      "doi": "10.1371/journal.pone.0256436",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34432811/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "CCGA1_and2_NCT02889978",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C8",
        "CSC1",
        "CSC3"
      ]
    },
    {
      "n": 9,
      "citation": "Tang WHW, Yimer H, Tummala M et al. Performance of a targeted methylation-based multi-cancer early detection test by race and ethnicity. Preventive medicine. 2023.",
      "tier": "A",
      "kind": "secondary_diagnostic_subgroup_analysis",
      "pmid": "36495927",
      "doi": "10.1016/j.ypmed.2022.107384",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36495927/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "CCGA3_NCT02889978",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C9",
        "CSC1"
      ]
    },
    {
      "n": 10,
      "citation": "Schrag D, Beer TM, McDonnell CH et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet (London, England). 2023.",
      "tier": "A",
      "kind": "primary",
      "pmid": "37805216",
      "doi": "10.1016/S0140-6736(23)01700-2",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37805216/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PATHFINDER_NCT04241796",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C10",
        "CSC1",
        "CSC2",
        "CSC4",
        "CH"
      ]
    },
    {
      "n": 11,
      "citation": "Lennon AM, Buchanan AH, Kinde I et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science (New York, N.Y.). 2020.",
      "tier": "A",
      "kind": "primary",
      "pmid": "32345712",
      "doi": "10.1126/science.abb9601",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32345712/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID32345712",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C11",
        "CSC1",
        "CSC2",
        "CSC4"
      ]
    },
    {
      "n": 12,
      "citation": "Bao H, Yang S, Chen X et al. Early detection of multiple cancer types using multidimensional cell-free DNA fragmentomics. Nature medicine. 2025.",
      "tier": "A",
      "kind": "primary",
      "pmid": "40425843",
      "doi": "10.1038/s41591-025-03735-2",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40425843/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID40425843",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C12",
        "CSC1"
      ]
    },
    {
      "n": 13,
      "citation": "Taylor MS, Wu C, Fridy PC et al. Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker. Cancer discovery. 2023.",
      "tier": "A",
      "kind": "primary",
      "pmid": "37698949",
      "doi": "10.1158/2159-8290.CD-23-0313",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37698949/",
      "status_flags": [
        "UpdateOf: PMID36747644",
        "ErratumIn: PMID39228301"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID37698949",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C13",
        "CSC1"
      ]
    },
    {
      "n": 14,
      "citation": "Gao Q, Lin YP, Li BS et al. Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies. Annals of oncology : official journal of the European Society for Medical Oncology. 2023.",
      "tier": "A",
      "kind": "primary",
      "pmid": "36849097",
      "doi": "10.1016/j.annonc.2023.02.010",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36849097/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID36849097",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C14",
        "CSC1",
        "CSC3"
      ]
    },
    {
      "n": 15,
      "citation": "Jin F, Yang P, Xu R et al. Phosphatidylserine-positive extracellular vesicles for detecting multiple operable cancers. Cell reports. 2025.",
      "tier": "A",
      "kind": "primary",
      "pmid": "40934080",
      "doi": "10.1016/j.celrep.2025.116259",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40934080/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID40934080",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C15",
        "CSC1"
      ]
    },
    {
      "n": 16,
      "citation": "Wang Y, Joshu CE, Curtis SD et al. Detection of Cancers Three Years prior to Diagnosis Using Plasma Cell-Free DNA. Cancer discovery. 2025.",
      "tier": "A",
      "kind": "primary",
      "pmid": "40402478",
      "doi": "10.1158/2159-8290.CD-25-0375",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40402478/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID40402478",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C16",
        "CSC1",
        "CSC3"
      ]
    },
    {
      "n": 17,
      "citation": "Dong W, Lau CH, Li J et al. Pan-cancer methylation analysis of circulating cell-free DNA. Cancer genetics. 2025.",
      "tier": "A",
      "kind": "primary",
      "pmid": "40737714",
      "doi": "10.1016/j.cancergen.2025.07.014",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40737714/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID40737714",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C17",
        "CSC1",
        "CSC2"
      ]
    },
    {
      "n": 18,
      "citation": "Matrana M, Shukla V, Kingsbury D et al. Real-world data and clinical experience from over 100,000 multi-cancer early detection tests. Nature communications. 2025.",
      "tier": "A",
      "kind": "primary",
      "pmid": "41173830",
      "doi": "10.1038/s41467-025-64094-7",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41173830/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID41173830",
      "access_depth": "full_text_partial",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Results:paragraph5, 1:Results:paragraph6, 1:Results:paragraph12, 1:Results:paragraph13, 3:Methods:paragraph1, 3:Methods:paragraph2, 3:Methods:paragraph3, 3:Methods:paragraph4. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C18",
        "CSC1",
        "CSC2"
      ]
    },
    {
      "n": 19,
      "citation": "Nguyen VTC, Nguyen TH, Doan NNT et al. Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization. eLife. 2023.",
      "tier": "A",
      "kind": "primary",
      "pmid": "37819044",
      "doi": "10.7554/eLife.89083",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37819044/",
      "status_flags": [
        "UpdateOf: PMID not supplied",
        "UpdateOf: PMID not supplied",
        "UpdateOf: PMID not supplied"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "SPOTMAS_case_control_development",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C19",
        "CSC1"
      ]
    },
    {
      "n": 20,
      "citation": "Michel M, Heidary M, Mechri A et al. Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025.",
      "tier": "A",
      "kind": "primary",
      "pmid": "39620930",
      "doi": "10.1158/1078-0432.CCR-24-2669",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39620930/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID39620930",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C20",
        "CSC1"
      ]
    },
    {
      "n": 21,
      "citation": "Zhang J, Rui H, Hu H. Noninvasive multi-cancer detection using blood-based cell-free microRNAs. Scientific reports. 2024.",
      "tier": "A",
      "kind": "primary",
      "pmid": "39333750",
      "doi": "10.1038/s41598-024-73783-0",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39333750/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID39333750",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C21",
        "CSC1"
      ]
    },
    {
      "n": 22,
      "citation": "Fang J, Luo S, Li S et al. Detection of primary cancer types via fragment size selection in circulating cell-free extrachromosomal circular DNA. Genome medicine. 2026.",
      "tier": "A",
      "kind": "primary",
      "pmid": "41495807",
      "doi": "10.1186/s13073-025-01595-6",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41495807/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID41495807",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C22",
        "CSC1"
      ]
    },
    {
      "n": 23,
      "citation": "Bratulic S, Limeta A, Dabestani S et al. Noninvasive detection of any-stage cancer using free glycosaminoglycans. Proceedings of the National Academy of Sciences of the United States of America. 2022.",
      "tier": "A",
      "kind": "primary",
      "pmid": "36469776",
      "doi": "10.1073/pnas.2115328119",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36469776/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID36469776",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C23",
        "CSC1",
        "CSC3"
      ]
    },
    {
      "n": 24,
      "citation": "Brito-Rocha T, Constâncio V, Leite-Silva P et al. Multi-cancer early detection via a DNA methylation multiplex ddPCR-based blood test. International journal of cancer. 2025.",
      "tier": "A",
      "kind": "primary",
      "pmid": "40317486",
      "doi": "10.1002/ijc.35467",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40317486/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID40317486",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C24",
        "CSC1"
      ]
    },
    {
      "n": 25,
      "citation": "Huang A, Guo DZ, Su ZX et al. GUIDE: a prospective cohort study for blood-based early detection of gastrointestinal cancers using targeted DNA methylation and fragmentomics sequencing. Molecular cancer. 2025.",
      "tier": "A",
      "kind": "primary",
      "pmid": "40468355",
      "doi": "10.1186/s12943-025-02367-x",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40468355/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID40468355",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C25",
        "CSC1"
      ]
    },
    {
      "n": 26,
      "citation": "Nguyen LHD, Nguyen THH, Le VH et al. Prospective validation study: a non-invasive circulating tumor DNA-based assay for simultaneous early detection of multiple cancers in asymptomatic adults. BMC medicine. 2025.",
      "tier": "A",
      "kind": "primary",
      "pmid": "39948555",
      "doi": "10.1186/s12916-025-03929-y",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39948555/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "K_DETEK_NCT05227261",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C26",
        "CSC1",
        "CSC2"
      ]
    },
    {
      "n": 27,
      "citation": "Curtis SD, Liu T, Bai Y et al. Fragmentation signatures in cancer patients resemble those of patients with vascular or autoimmune diseases. Proceedings of the National Academy of Sciences of the United States of America. 2025.",
      "tier": "A",
      "kind": "primary",
      "pmid": "40833414",
      "doi": "10.1073/pnas.2426890122",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40833414/",
      "status_flags": [
        "ErratumIn: PMID41628341"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID40833414",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C27",
        "CSC1"
      ]
    },
    {
      "n": 28,
      "citation": "Held D, Bolland S, Freese R et al. A Protein-Based Blood Test for Multi-Cancer Diagnostics. Biomedicines. 2025.",
      "tier": "A",
      "kind": "primary",
      "pmid": "41153790",
      "doi": "10.3390/biomedicines13102510",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41153790/",
      "status_flags": [
        "ErratumIn: PMID41595793"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID41153790",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C28",
        "CSC1"
      ]
    },
    {
      "n": 29,
      "citation": "Hinestrosa JP, Kurzrock R, Lewis JM et al. Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test. Communications medicine. 2022.",
      "tier": "A",
      "kind": "primary",
      "pmid": "35603292",
      "doi": "10.1038/s43856-022-00088-6",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35603292/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID35603292",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C29",
        "CSC1"
      ]
    },
    {
      "n": 30,
      "citation": "Marinac CR, O'Donnell EK, Clarke CA et al. Multicancer Early Detection Blood Test Performance in Cancer Survivors From the PATHFINDER Study. JCO precision oncology. 2025.",
      "tier": "A",
      "kind": "secondary_trial_diagnostic_report",
      "pmid": "41411611",
      "doi": "10.1200/PO-25-00498",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41411611/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PATHFINDER_NCT04241796",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C30",
        "CSC1",
        "CSC2"
      ]
    },
    {
      "n": 31,
      "citation": "Nadauld L, McDonnell CH, Dilaveri CA et al. Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study. The Lancet. Oncology. 2025.",
      "tier": "A",
      "kind": "secondary_patient_reported_outcomes",
      "pmid": "39818231",
      "doi": "10.1016/S1470-2045(24)00645-4",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39818231/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PATHFINDER_NCT04241796",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C31",
        "CSC1",
        "CSC4"
      ]
    },
    {
      "n": 32,
      "citation": "Marlow LAV, Schmeising-Barnes N, Waller J. The impact of cancer expectations on psychological responses following a cancer signal detected result in asymptomatic multi-cancer detection (MCED) testing. British journal of cancer. 2025.",
      "tier": "A",
      "kind": "original_qualitative_trial_substudy",
      "pmid": "40926064",
      "doi": "10.1038/s41416-025-03180-5",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40926064/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "NHS_Galleri_NCT05611632",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C32",
        "CSC1",
        "CSC4"
      ]
    },
    {
      "n": 33,
      "citation": "Schmeising-Barnes N, Waller J, Marlow LAV. Attitudes to multi-cancer early detection (MCED) blood tests for population-based screening: A qualitative study in Great Britain. Social science & medicine (1982). 2024.",
      "tier": "A",
      "kind": "original_qualitative_focus_groups",
      "pmid": "38520825",
      "doi": "10.1016/j.socscimed.2024.116762",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38520825/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID38520825",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C33",
        "CSC1",
        "CSC4"
      ]
    },
    {
      "n": 34,
      "citation": "Turriff AE, Annunziata CM, Malayeri AA et al. Prenatal cfDNA Sequencing and Incidental Detection of Maternal Cancer. The New England journal of medicine. 2024.",
      "tier": "A",
      "kind": "primary",
      "pmid": "39774314",
      "doi": "10.1056/NEJMoa2401029",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39774314/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID39774314",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C34",
        "CSC1",
        "CSC4"
      ]
    },
    {
      "n": 35,
      "citation": "Cohen JD, Li L, Wang Y et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science (New York, N.Y.). 2018.",
      "tier": "A",
      "kind": "primary",
      "pmid": "29348365",
      "doi": "10.1126/science.aar3247",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29348365/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID29348365",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C35",
        "CSC1"
      ]
    },
    {
      "n": 36,
      "citation": "Chen X, Gole J, Gore A et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nature communications. 2020.",
      "tier": "A",
      "kind": "primary",
      "pmid": "32694610",
      "doi": "10.1038/s41467-020-17316-z",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32694610/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID32694610",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C36",
        "CSC1",
        "CSC3"
      ]
    },
    {
      "n": 37,
      "citation": "Villani A, Shore A, Wasserman JD et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. The Lancet. Oncology. 2016.",
      "tier": "A",
      "kind": "primary",
      "pmid": "27501770",
      "doi": "10.1016/S1470-2045(16)30249-2",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27501770/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "TP53_comprehensive_surveillance_89",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C37",
        "CSC4"
      ]
    },
    {
      "n": 38,
      "citation": "Omran M, Tham E, Brandberg Y et al. Whole-Body MRI Surveillance-Baseline Findings in the Swedish Multicentre Hereditary TP53-Related Cancer Syndrome Study (SWEP53). Cancers. 2022.",
      "tier": "A",
      "kind": "primary",
      "pmid": "35053544",
      "doi": "10.3390/cancers14020380",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35053544/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "SWEP53_TP53_baseline",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C38",
        "CSC4"
      ]
    },
    {
      "n": 39,
      "citation": "Schmidt CO, Sierocinski E, Hegenscheid K et al. Impact of whole-body MRI in a general population study. European journal of epidemiology. 2016.",
      "tier": "A",
      "kind": "primary",
      "pmid": "26597793",
      "doi": "10.1007/s10654-015-0101-y",
      "url": "https://pubmed.ncbi.nlm.nih.gov/26597793/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "SHIP_Trend_whole_body_MRI",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C39",
        "CSC4"
      ]
    },
    {
      "n": 40,
      "citation": "Schmidt CO, Sierocinski E, Baumeister S et al. Effects of whole-body MRI on outpatient health service costs: a general-population prospective cohort study in Mecklenburg-Vorpommern, Germany. BMJ open. 2022.",
      "tier": "A",
      "kind": "primary",
      "pmid": "34996801",
      "doi": "10.1136/bmjopen-2021-056572",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34996801/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "SHIP_and_SHIPTrend_MRI",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C40",
        "CSC4"
      ]
    },
    {
      "n": 41,
      "citation": "Sodde P, Hyder Z, Pugh S et al. Evaluation of whole-body MRI for cancer early detection in Li-Fraumeni syndrome. Journal of medical genetics. 2025.",
      "tier": "A",
      "kind": "primary",
      "pmid": "40588398",
      "doi": "10.1136/jmg-2025-110704",
      "url": "https://pubmed.ncbi.nlm.nih.gov/40588398/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID40588398",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C41",
        "CSC4"
      ]
    },
    {
      "n": 42,
      "citation": "Morin SH, Cobbold JF, Lim AK et al. Incidental findings in healthy control research subjects using whole-body MRI. European journal of radiology. 2009.",
      "tier": "A",
      "kind": "primary",
      "pmid": "18818038",
      "doi": "10.1016/j.ejrad.2008.08.006",
      "url": "https://pubmed.ncbi.nlm.nih.gov/18818038/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID18818038",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C42",
        "CSC4"
      ]
    },
    {
      "n": 43,
      "citation": "Ulus S, Suleyman E, Ozcan UA et al. Whole-Body MRI Screening in Asymptomatic Subjects; Preliminary Experience and Long-Term Follow-Up Findings. Polish journal of radiology. 2016.",
      "tier": "A",
      "kind": "primary",
      "pmid": "27635171",
      "doi": "10.12659/PJR.897570",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27635171/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID27635171",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C43",
        "CSC4"
      ]
    },
    {
      "n": 44,
      "citation": "Hegenscheid K, Seipel R, Schmidt CO et al. Potentially relevant incidental findings on research whole-body MRI in the general adult population: frequencies and management. European radiology. 2013.",
      "tier": "A",
      "kind": "primary",
      "pmid": "22911290",
      "doi": "10.1007/s00330-012-2636-6",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22911290/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "SHIP_whole_body_MRI",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C44",
        "CSC4"
      ]
    },
    {
      "n": 45,
      "citation": "Richter A, Sierocinski E, Singer S et al. The effects of incidental findings from whole-body MRI on the frequency of biopsies and detected malignancies or benign conditions in a general population cohort study. European journal of epidemiology. 2020.",
      "tier": "A",
      "kind": "primary",
      "pmid": "32860149",
      "doi": "10.1007/s10654-020-00679-4",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32860149/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "SHIP_and_SHIPTrend_MRI",
      "access_depth": "full_text_partial",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph3, 1:Methods:paragraph4, 1:Methods:paragraph10, 1:Methods:paragraph23, 2:Results:paragraph1, 2:Results:paragraph7, 2:Results:paragraph14. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C45",
        "CSC4"
      ]
    },
    {
      "n": 46,
      "citation": "Schmidt CO, Hegenscheid K, Erdmann P et al. Psychosocial consequences and severity of disclosed incidental findings from whole-body MRI in a general population study. European radiology. 2013.",
      "tier": "A",
      "kind": "primary",
      "pmid": "23239059",
      "doi": "10.1007/s00330-012-2723-8",
      "url": "https://pubmed.ncbi.nlm.nih.gov/23239059/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "SHIP_whole_body_MRI",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C46",
        "CSC4"
      ]
    },
    {
      "n": 47,
      "citation": "Tandy-Connor S, Guiltinan J, Krempely K et al. False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care. Genetics in medicine : official journal of the American College of Medical Genetics. 2018.",
      "tier": "A",
      "kind": "primary",
      "pmid": "29565420",
      "doi": "10.1038/gim.2018.38",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29565420/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID29565420",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C47",
        "CSC4"
      ]
    },
    {
      "n": 48,
      "citation": "National Lung Screening Trial Research Team, Aberle DR, Adams AM et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. The New England journal of medicine. 2011.",
      "tier": "A",
      "kind": "rct",
      "pmid": "21714641",
      "doi": "10.1056/NEJMoa1102873",
      "url": "https://pubmed.ncbi.nlm.nih.gov/21714641/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "NLST_NCT00047385",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C48",
        "CSC2",
        "CSC3"
      ]
    },
    {
      "n": 49,
      "citation": "de Koning HJ, van der Aalst CM, de Jong PA et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. The New England journal of medicine. 2020.",
      "tier": "A",
      "kind": "rct",
      "pmid": "31995683",
      "doi": "10.1056/NEJMoa1911793",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31995683/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "NELSON_NL580",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C49",
        "CSC2",
        "CSC3"
      ]
    },
    {
      "n": 50,
      "citation": "National Lung Screening Trial Research Team. Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019.",
      "tier": "A",
      "kind": "randomized_trial_long_term_followup",
      "pmid": "31260833",
      "doi": "10.1016/j.jtho.2019.05.044",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31260833/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "NLST_NCT00047385",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C50",
        "CSC2",
        "CSC3"
      ]
    },
    {
      "n": 51,
      "citation": "Menon U, Gentry-Maharaj A, Burnell M et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet (London, England). 2021.",
      "tier": "A",
      "kind": "rct",
      "pmid": "33991479",
      "doi": "10.1016/S0140-6736(21)00731-5",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33991479/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "UKCTOCS_NCT00058032",
      "access_depth": "full_text_partial",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph0, 1:Methods:paragraph4, 1:Methods:paragraph8, 1:Methods:paragraph11, 2:Results:paragraph3, 2:Results:paragraph11, 2:Results:paragraph16. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C51",
        "CSC2",
        "CSC3",
        "CH"
      ]
    },
    {
      "n": 52,
      "citation": "Menon U, Gentry-Maharaj A, Burnell M et al. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial. Health technology assessment (Winchester, England). 2025.",
      "tier": "A",
      "kind": "original_comprehensive_trial_report",
      "pmid": "37183782",
      "doi": "10.3310/BHBR5832",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37183782/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "UKCTOCS_NCT00058032",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C52",
        "CSC2",
        "CSC3",
        "CSC4"
      ]
    },
    {
      "n": 53,
      "citation": "Martin RM, Turner EL, Young GJ et al. Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial. JAMA. 2024.",
      "tier": "A",
      "kind": "rct",
      "pmid": "38581198",
      "doi": "10.1001/jama.2024.4011",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38581198/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "CAP_ISRCTN92187251",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C53",
        "CSC2",
        "CSC3"
      ]
    },
    {
      "n": 54,
      "citation": "Bretthauer M, Løberg M, Wieszczy P et al. Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death. The New England journal of medicine. 2022.",
      "tier": "A",
      "kind": "rct",
      "pmid": "36214590",
      "doi": "10.1056/NEJMoa2208375",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36214590/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "NordICC_NCT00883792",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C54",
        "CSC2",
        "CSC3"
      ]
    },
    {
      "n": 55,
      "citation": "Kaminski MF, Kalager M, Løberg M et al. Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial. Lancet (London, England). 2026.",
      "tier": "A",
      "kind": "randomized_trial_long_term_followup",
      "pmid": "42102826",
      "doi": "10.1016/S0140-6736(26)00508-8",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42102826/",
      "status_flags": [
        "ErratumIn: PMID42119586"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "NordICC_NCT00883792",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C55",
        "CSC2",
        "CSC3"
      ]
    },
    {
      "n": 56,
      "citation": "Roobol MJ, de Vos II, Månsson M et al. European Study of Prostate Cancer Screening - 23-Year Follow-up. The New England journal of medicine. 2025.",
      "tier": "A",
      "kind": "rct",
      "pmid": "41160819",
      "doi": "10.1056/NEJMoa2503223",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41160819/",
      "status_flags": [
        "ErratumIn: PMID41812212"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "ERSPC_ISRCTN49127736",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C56",
        "CSC2",
        "CSC3"
      ]
    },
    {
      "n": 57,
      "citation": "Duffy SW, Vulkan D, Cuckle H et al. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. The Lancet. Oncology. 2020.",
      "tier": "A",
      "kind": "rct",
      "pmid": "32800099",
      "doi": "10.1016/S1470-2045(20)30398-3",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32800099/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "PMID32800099",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C57",
        "CSC2",
        "CSC3"
      ]
    },
    {
      "n": 58,
      "citation": "Field JK, Duffy SW, Baldwin DR et al. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health technology assessment (Winchester, England). 2016.",
      "tier": "A",
      "kind": "rct",
      "pmid": "27224642",
      "doi": "10.3310/hta20400",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27224642/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-10-13",
      "status_checked_on": "2026-10-13",
      "study_id": "UKLS_ISRCTN78513845",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C58",
        "CSC1",
        "CSC2",
        "CSC3"
      ]
    },
    {
      "n": 59,
      "citation": "Nabavizadeh N, McDonnell C, Kurbegov D et al. Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study. Nature medicine. 2026.",
      "tier": "A",
      "kind": "primary",
      "pmid": "42773207",
      "doi": "10.1038/s41591-026-04618-w",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42773207/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-11-02",
      "status_checked_on": "2026-11-02",
      "study_id": "PATHFINDER2_NCT05155605",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original abstract and PubMed metadata examined 2026-11-02 during the adversarial correction; no complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C59",
        "CSC1"
      ]
    },
    {
      "n": 60,
      "citation": "Feng X, Zahed H, Onwuka J et al. Cancer Stage Compared With Mortality as End Points in Randomized Clinical Trials of Cancer Screening: A Systematic Review and Meta-Analysis. JAMA. 2024.",
      "tier": "B",
      "kind": "systematic_review_meta_analysis",
      "pmid": "38583868",
      "doi": "10.1001/jama.2024.5814",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38583868/",
      "status_flags": [
        "none_found"
      ],
      "opened": true,
      "opened_on": "2026-11-02",
      "status_checked_on": "2026-11-02",
      "study_id": "PMID38583868",
      "access_depth": "abstract_metadata",
      "access_note": "Bounded original abstract and PubMed metadata examined 2026-11-02 during the adversarial correction; no complete-paper or supplement audit claimed.",
      "carries_claims": [
        "C60",
        "CSC3"
      ]
    }
  ],
  "independence_basis": {
    "required": false,
    "lines": [],
    "shared_failure_mode_checked": true,
    "note": "No subclaim or model reaches Ζ. The model-level Ε rests on contextual clinical screening effects with explicit positive/null programme boundaries, not an assertion of independently failing Galleri mortality lines. NHS, CCGA, PATHFINDER, SHIP and comparator follow-ups are grouped; different biomarkers or report dates do not create new allocation trials."
  },
  "gamma_hard_rules_considered": [
    {
      "subclaim_id": "SC1",
      "rule_quoted": "Sphere formation alone",
      "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale."
    },
    {
      "subclaim_id": "SC1",
      "rule_quoted": "Marker enrichment alone",
      "trigger_status": "Not triggered literally as a cancer-stemness rule. The separate universal signal-to-clinical-benefit cap applies only to the causal translation, not diagnostic accuracy itself."
    },
    {
      "subclaim_id": "SC1",
      "rule_quoted": "Xenograft tumor-initiation without lineage-resolved endogenous evidence",
      "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale."
    },
    {
      "subclaim_id": "SC1",
      "rule_quoted": "In vitro-only mechanistic studies, however elegant",
      "trigger_status": "Not triggered: SC1 evidence is human prospective screening and randomized-arm diagnostic data; no in vitro-only class is offered."
    },
    {
      "subclaim_id": "SC2",
      "rule_quoted": "Sphere formation alone",
      "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale."
    },
    {
      "subclaim_id": "SC2",
      "rule_quoted": "Marker enrichment alone",
      "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale."
    },
    {
      "subclaim_id": "SC2",
      "rule_quoted": "Xenograft tumor-initiation without lineage-resolved endogenous evidence",
      "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale."
    },
    {
      "subclaim_id": "SC2",
      "rule_quoted": "In vitro-only mechanistic studies, however elegant",
      "trigger_status": "Not triggered: directly studied human screening is evaluated through the disclosed clinical equivalent; the absent positive mortality outcome is the blocker."
    },
    {
      "subclaim_id": "SC3",
      "rule_quoted": "Sphere formation alone",
      "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale."
    },
    {
      "subclaim_id": "SC3",
      "rule_quoted": "Marker enrichment alone",
      "trigger_status": "Not triggered literally as a cancer-stemness rule; stage-to-mortality surrogate inference remains explicitly capped separately."
    },
    {
      "subclaim_id": "SC3",
      "rule_quoted": "Xenograft tumor-initiation without lineage-resolved endogenous evidence",
      "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale."
    },
    {
      "subclaim_id": "SC3",
      "rule_quoted": "In vitro-only mechanistic studies, however elegant",
      "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale."
    },
    {
      "subclaim_id": "SC4",
      "rule_quoted": "Sphere formation alone",
      "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale."
    },
    {
      "subclaim_id": "SC4",
      "rule_quoted": "Marker enrichment alone",
      "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale."
    },
    {
      "subclaim_id": "SC4",
      "rule_quoted": "Xenograft tumor-initiation without lineage-resolved endogenous evidence",
      "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale."
    },
    {
      "subclaim_id": "SC4",
      "rule_quoted": "In vitro-only mechanistic studies, however elegant",
      "trigger_status": "Not triggered literally for this assembled scoped case. Any adapted clinical, proxy or system-inference restriction is stated separately in the subclaim rationale."
    }
  ],
  "supplementary_source_checks": [],
  "consensus_validation": {
    "completed": true,
    "status": "completed_original_source_reconciliation",
    "provider_mode": "Consensus Pro signed-in browser; observed output and citation link mappings",
    "queries": [
      "https://consensus.app/search/multicancer-blood-screening-efficacy/ZzzZhHUFRWyztsWRokrbig/"
    ],
    "query_record_note": "Exact provider question/response retained privately in its retrieval receipt.",
    "primary_comparison_count": 9,
    "primary_comparisons": [
      {
        "pmid": "42776074",
        "doi": "10.1056/NEJMoa2505723",
        "source_type": "primary study report",
        "study_group": "NHS_Galleri_NCT05611632",
        "access_depth": "abstract_metadata",
        "consensus_aspect": "Current NHS randomized trial, endpoint hierarchy and age denominator",
        "result_comparison": "Consensus correctly reports a failed primary stageIII/IV endpoint and a favorable secondary stageIV contrast, but uses142924 enrolled participants aged50–79. The original primary report actually randomized142250 aged50–77. It gives primary IRR1.03,95%CI0.92–1.14,P=.63 and secondary stageIV IRR0.86,CI0.74–1.00. Neither endpoint is mortality. The publisher confirms online publication22September2026; the official trial site says cancer-death analyses continue. Provider 'No' is interpreted as benefit unestablished, not a completed death trial proving no effect. Additional provider event counts not verified at original abstract depth are not adopted.",
        "original_source": "https://pubmed.ncbi.nlm.nih.gov/42776074/",
        "source_examination_receipts": [
          "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\mced-cancer-mortality\\examinations\\original-0-9-10000.json"
        ],
        "body_receipts": []
      },
      {
        "pmid": "42773209",
        "doi": "10.1038/s41591-026-04652-8",
        "source_type": "primary study report",
        "study_group": "NHS_Galleri_NCT05611632",
        "access_depth": "abstract_metadata",
        "consensus_aspect": "NHS diagnostic performance is descriptive and round specific",
        "result_comparison": "Consensus's general high-specificity and tissue-origin discussion is supported, but original metrics are reported by round rather than as one universal percentage. PPV58.0%,50.4%,45.8% and all-cancer episode sensitivity26.7–37.2% accompany specificity99.5–99.6%;937 detected primary cancers are from the same NHS parent. These descriptive analyses had no hypothesis testing. A high NPV does not establish absence of every cancer or saved lives.",
        "original_source": "https://pubmed.ncbi.nlm.nih.gov/42773209/",
        "source_examination_receipts": [
          "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\mced-cancer-mortality\\examinations\\original-0-9-10000.json"
        ],
        "body_receipts": []
      },
      {
        "pmid": "37805216",
        "doi": "10.1016/S0140-6736(23)01700-2",
        "source_type": "primary study report",
        "study_group": "PATHFINDER_NCT04241796",
        "access_depth": "abstract_metadata",
        "consensus_aspect": "PATHFINDER predictive value, workup and false-positive denominators",
        "result_comparison": "Consensus accurately identifies6621 evaluable participants,92signals,35 confirmed cancers,57 false positives and median162-day false-positive diagnostic resolution. The original abstract reports procedures in17 of57 false positives.62% is the proportion among positive signals, not among all screened people. The provider's86 negative-screen cancers/sensitivity29.5% were not verified from the available original abstract or body at this access depth and are not used as load-bearing source facts. Public XML returned500; the receipt remains abstract/status.",
        "original_source": "https://pubmed.ncbi.nlm.nih.gov/37805216/",
        "source_examination_receipts": [
          "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\mced-cancer-mortality\\examinations\\original-9-18-10000.json"
        ],
        "body_receipts": []
      },
      {
        "pmid": "41173830",
        "doi": "10.1038/s41467-025-64094-7",
        "source_type": "primary study report",
        "study_group": "PMID41173830",
        "access_depth": "full_text_partial",
        "consensus_aspect": "Real-world denominator and ascertainment repair",
        "result_comparison": "Consensus groups prospective/ambulatory PPVs into ranges without resolving this series' incomplete outcome ascertainment. Actual original Methods/Results show111080 test results,1011 positives,459 voluntary outcome reports and411 completed workups. Among completed asymptomatic workups,128 of259 had invasive cancer, ePPV49.4%; symptomatic and known-active-cancer orders are different populations. Negative outcomes were not collected systematically. Neither the overall test count nor selected reported outcomes establish complete screening sensitivity or mortality benefit.",
        "original_source": "https://pubmed.ncbi.nlm.nih.gov/41173830/",
        "source_examination_receipts": [
          "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\mced-cancer-mortality\\examinations\\original-9-18-10000.json"
        ],
        "body_receipts": [
          "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\mced-cancer-mortality\\body-presentation-receipts\\41173830-s1-p5-6-12-13.json",
          "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\mced-cancer-mortality\\body-presentation-receipts\\41173830-s3-p1-2-3-4.json"
        ]
      },
      {
        "pmid": "34176681",
        "doi": "10.1016/j.annonc.2021.05.806",
        "source_type": "primary study report",
        "study_group": "CCGA3_NCT02889978",
        "access_depth": "abstract_metadata",
        "consensus_aspect": "CCGA stage sensitivity and transportability",
        "result_comparison": "Consensus's approximately17% stageI versus90% stageIV sensitivities match the original CCGA validation abstract:16.8% and90.1%. The study included4077 validation participants with2823 known cancers and1254 controls. That case-control spectrum and prevalence differ from prospective population screening, so these values do not replace NHS screening episode sensitivity or directly validate a mortality model.",
        "original_source": "https://pubmed.ncbi.nlm.nih.gov/34176681/",
        "source_examination_receipts": [
          "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\mced-cancer-mortality\\examinations\\original-0-9-10000.json"
        ],
        "body_receipts": []
      },
      {
        "pmid": "33991479",
        "doi": "10.1016/S0140-6736(21)00731-5",
        "source_type": "primary study report",
        "study_group": "UKCTOCS_NCT00058032",
        "access_depth": "full_text_partial",
        "consensus_aspect": "Original counterexample to universal stage-to-mortality translation",
        "result_comparison": "Consensus discusses screening biases but does not resolve this decisive original mortality comparator. Selected original UKCTOCS Methods/Results verify randomized intention-to-screen analysis, masked outcome review and16.3-year median follow-up. Multimodal screening yielded47.2% more stageI and24.5% fewer stageIV ovarian/tubal cancers, while deaths did not fall (primaryP=.58). This directly challenges a universal stage-surrogate bridge without deciding the eventual Galleri death endpoint.",
        "original_source": "https://pubmed.ncbi.nlm.nih.gov/33991479/",
        "source_examination_receipts": [
          "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\mced-cancer-mortality\\examinations\\original-45-52-10000.json"
        ],
        "body_receipts": [
          "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\mced-cancer-mortality\\body-presentation-receipts\\33991479-s1-p0-4-8-11.json",
          "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\mced-cancer-mortality\\body-presentation-receipts\\33991479-s2-p3-11-16.json"
        ]
      },
      {
        "pmid": "32345712",
        "doi": "10.1126/science.abb9601",
        "source_type": "primary study report",
        "study_group": "PMID32345712",
        "access_depth": "abstract_metadata",
        "consensus_aspect": "DETECT-A omitted clinical pathway distinction",
        "result_comparison": "The prompt requested DETECT-A, but the observed provider answer does not adjudicate its original details. The original prospective report found26 cancers by blood testing,24 via usual screening and46 by neither in10006 women, with a different blood-test/PETCT package. Nine of15 who underwent PETCT had surgical excision, and0.22% of all participants had a futile invasive procedure. Curative-intent treatment is preserved but is not proven cure or a randomized death benefit.",
        "original_source": "https://pubmed.ncbi.nlm.nih.gov/32345712/",
        "source_examination_receipts": [
          "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\mced-cancer-mortality\\examinations\\original-9-18-10000.json"
        ],
        "body_receipts": []
      },
      {
        "pmid": "32860149",
        "doi": "10.1007/s10654-020-00679-4",
        "source_type": "primary study report",
        "study_group": "SHIP_and_SHIPTrend_MRI",
        "access_depth": "full_text_partial",
        "consensus_aspect": "Whole-body MRI burdens require MRI originals",
        "result_comparison": "The provider table cites a blood-screening study for generic whole-body MRI claims. Actual SHIP original Methods/Results show optional MRI participation plus laboratory disclosures, biopsy-rate increase from6.9 to9.9 per100 observation-years and predominately nonmalignant results, with regional biopsy coverage limits. This supplies MRI-specific cascade evidence, while selection/concurrent disclosure prevents a claim that every additional biopsy was caused by MRI or that net clinical harm is established.",
        "original_source": "https://pubmed.ncbi.nlm.nih.gov/32860149/",
        "source_examination_receipts": [
          "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\mced-cancer-mortality\\examinations\\original-36-45-10000.json"
        ],
        "body_receipts": [
          "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\mced-cancer-mortality\\body-presentation-receipts\\32860149-s1-p3-4-10-23.json",
          "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\mced-cancer-mortality\\body-presentation-receipts\\32860149-s2-p1-7-14.json"
        ]
      },
      {
        "pmid": "29565420",
        "doi": "10.1038/gim.2018.38",
        "source_type": "primary study report",
        "study_group": "PMID29565420",
        "access_depth": "abstract_metadata",
        "consensus_aspect": "DTC raw-data confirmation is not a universal error rate",
        "result_comparison": "Consensus describes DTC genomic actionability/anxiety broadly without an exact original quantitative comparison. The original49-sample referred confirmation series found40% of reported variants false positive, and some increased-risk labels benign. Referral enrichment and the variant denominator are central: this is not40% of all customers or regulated consumer test results. It also does not establish that DTC risk genotyping has the same purpose or clinical effect as MCED screening.",
        "original_source": "https://pubmed.ncbi.nlm.nih.gov/29565420/",
        "source_examination_receipts": [
          "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\mced-cancer-mortality\\examinations\\original-45-52-10000.json"
        ],
        "body_receipts": []
      }
    ],
    "grade_changed": false,
    "grade_change_note": "Source-based adjudication; no independent blinded regrade claimed.",
    "raw_receipts": [
      {
        "path": "deliverables\\hsef_v53_traffic_ranks_16_20_2026-10-13\\mced-cancer-mortality\\consensus-browser-2026-10-13.json",
        "sha256": "c10548cbca5d059c138064783869036ada03b647daf2b2e55ddd2ab6436e7256"
      }
    ],
    "independent_blinded_audit": false,
    "cutoff": "2026-10-13",
    "completed_utc": "2026-10-13T17:35:23.602153+00:00",
    "conclusion": "Endpoint hierarchy, experimental scope and original-source limits determine the evidence cards; provider wording does not override them."
  }
}